<SEC-DOCUMENT>0000059478-23-000025.txt : 20230202
<SEC-HEADER>0000059478-23-000025.hdr.sgml : 20230202
<ACCEPTANCE-DATETIME>20230202071344
ACCESSION NUMBER:		0000059478-23-000025
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230202
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230202
DATE AS OF CHANGE:		20230202

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ELI LILLY & Co
		CENTRAL INDEX KEY:			0000059478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				350470950
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-06351
		FILM NUMBER:		23578775

	BUSINESS ADDRESS:	
		STREET 1:		LILLY CORPORATE CTR
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285
		BUSINESS PHONE:		3172762000

	MAIL ADDRESS:	
		STREET 1:		LILLY CORPORATE CENTER
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LILLY ELI & CO
		DATE OF NAME CHANGE:	19941024
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lly-20230202.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:98b0e548-4886-4cc8-9807-a05ddcd110df,g:27793b14-51c9-40f9-928d-212481ae66bb,d:36186d4ec9284ff4a41b89da947a5125--><html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:lly="http://www.lilly.com/20230202" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lly-20230202</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV80L2ZyYWc6NzkwNWQ5M2ZjMDQxNDRjMmE1NzZkZThjMjYwYjNjYjAvdGFibGU6M2RhNjA0NDJmNmJjNDg3ZDkyOTM1MzllZGQ2Yzg1YmIvdGFibGVyYW5nZTozZGE2MDQ0MmY2YmM0ODdkOTI5MzUzOWVkZDZjODViYl8yLTEtMS0xLTE5NzIwNA_e466bccf-40c0-4056-a38f-8bec14a81e76">0000059478</ix:nonNumeric><ix:nonNumeric contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV80L2ZyYWc6NzkwNWQ5M2ZjMDQxNDRjMmE1NzZkZThjMjYwYjNjYjAvdGFibGU6M2RhNjA0NDJmNmJjNDg3ZDkyOTM1MzllZGQ2Yzg1YmIvdGFibGVyYW5nZTozZGE2MDQ0MmY2YmM0ODdkOTI5MzUzOWVkZDZjODViYl81LTEtMS0xLTE5NzIwNA_4abbc548-cc98-4d43-9ce5-52368243b882">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lly-20230202.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-02</xbrli:startDate><xbrli:endDate>2023-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if99194a62558408da3eaf072492056d6_D20230202-20230202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-02</xbrli:startDate><xbrli:endDate>2023-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66c6ae2792ff4b84a5ebbb81244eb4b3_D20230202-20230202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-02</xbrli:startDate><xbrli:endDate>2023-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92c908dd435545b08496ae4273d1083b_D20230202-20230202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-02</xbrli:startDate><xbrli:endDate>2023-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c813e1023704a5987a3b758b72289a4_D20230202-20230202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-02</xbrli:startDate><xbrli:endDate>2023-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26372fc909e145c3b425f3f58cb0c510_D20230202-20230202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-02</xbrli:startDate><xbrli:endDate>2023-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f5b20c214394dc8bc427934d0f5d13b_D20230202-20230202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A500NotesDue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-02</xbrli:startDate><xbrli:endDate>2023-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i696cdd16d5b148f9b8875c2c416d58e3_D20230202-20230202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-02</xbrli:startDate><xbrli:endDate>2023-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63b8eaf69bd6416a9096eda3d15fc666_D20230202-20230202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-02</xbrli:startDate><xbrli:endDate>2023-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaff8c4f2c594068b5d1f826b384e156_D20230202-20230202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-02</xbrli:startDate><xbrli:endDate>2023-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c6077d2ffa84ee1b11a5af3affa1b67_D20230202-20230202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-02</xbrli:startDate><xbrli:endDate>2023-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i001eb9c620264821a3025473010e03ac_D20230202-20230202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-02</xbrli:startDate><xbrli:endDate>2023-02-02</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i36186d4ec9284ff4a41b89da947a5125_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:1.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Washington, D.C. 20549</span></div></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:26.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.360%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:8.2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGV4dHJlZ2lvbjphNzRmMTliZWZkOGM0MTAwOTI4ZGNhZTQ4MDRmYTZjYl8xMTg5_faea5420-1047-49bd-97c2-2f2247377b8e">8-K</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:26.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.360%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:2.2pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:13.2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of Earliest Event Reported): <ix:nonNumeric contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGV4dHJlZ2lvbjphNzRmMTliZWZkOGM0MTAwOTI4ZGNhZTQ4MDRmYTZjYl8xNTk_569c3d59-1a3b-4f27-bceb-33903e69d40f">February 2, 2023</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:26.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.360%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGV4dHJlZ2lvbjphNzRmMTliZWZkOGM0MTAwOTI4ZGNhZTQ4MDRmYTZjYl8xMTg1_2866e962-fb1f-42b3-bc27-3cf0d61ed912">ELI LILLY AND COMPANY</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (Exact Name of Registrant as Specified in its Charter)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:26.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.360%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.978%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6NWFhNTBhM2RlYmNlNGVkODlkNGJjYzgzNzEyMDk2ZmEvdGFibGVyYW5nZTo1YWE1MGEzZGViY2U0ZWQ4OWQ0YmNjODM3MTIwOTZmYV8wLTAtMS0xLTE5NzIwNA_2c6088a3-cbb8-4bd0-a57b-e8e196a2fdb2">Indiana</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6NWFhNTBhM2RlYmNlNGVkODlkNGJjYzgzNzEyMDk2ZmEvdGFibGVyYW5nZTo1YWE1MGEzZGViY2U0ZWQ4OWQ0YmNjODM3MTIwOTZmYV8wLTItMS0xLTE5NzIwNA_2eded2bf-9fd2-489b-ba50-2f1424ff4841">001-06351</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6NWFhNTBhM2RlYmNlNGVkODlkNGJjYzgzNzEyMDk2ZmEvdGFibGVyYW5nZTo1YWE1MGEzZGViY2U0ZWQ4OWQ0YmNjODM3MTIwOTZmYV8wLTQtMS0xLTE5NzIwNA_e88bbfa3-b93f-4e1d-bacb-b606839c3ee9">35-0470950</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(State or Other Jurisdiction<br/>of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:21.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.059%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6OWJkNTRjY2VkZWFiNGFlMDk1NmU4NWZmNjU2MGFlNWEvdGFibGVyYW5nZTo5YmQ1NGNjZWRlYWI0YWUwOTU2ZTg1ZmY2NTYwYWU1YV8wLTAtMS0xLTE5NzIwNA_dbbabbef-98c8-4e26-b0a1-113c6f8a99f1">Lilly Corporate Center</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6OWJkNTRjY2VkZWFiNGFlMDk1NmU4NWZmNjU2MGFlNWEvdGFibGVyYW5nZTo5YmQ1NGNjZWRlYWI0YWUwOTU2ZTg1ZmY2NTYwYWU1YV8xLTAtMS0xLTE5NzIwNA_f96044e1-9fe0-46c3-8f9c-783249d66a84">Indianapolis,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6OWJkNTRjY2VkZWFiNGFlMDk1NmU4NWZmNjU2MGFlNWEvdGFibGVyYW5nZTo5YmQ1NGNjZWRlYWI0YWUwOTU2ZTg1ZmY2NTYwYWU1YV8xLTEtMS0xLTE5NzIwNA_a8c4a1f2-74d8-42f1-a49b-6647ed5393e1">Indiana</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6OWJkNTRjY2VkZWFiNGFlMDk1NmU4NWZmNjU2MGFlNWEvdGFibGVyYW5nZTo5YmQ1NGNjZWRlYWI0YWUwOTU2ZTg1ZmY2NTYwYWU1YV8xLTItMS0xLTE5NzIwNA_24c7516a-37ba-44a8-8ae6-38f0986c1e4d">46285</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Zip Code)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code: (<ix:nonNumeric contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGV4dHJlZ2lvbjphNzRmMTliZWZkOGM0MTAwOTI4ZGNhZTQ4MDRmYTZjYl8xMTg2_a8868aad-6d03-4eb0-a765-9a55adf84fe8">317</ix:nonNumeric>) <ix:nonNumeric contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGV4dHJlZ2lvbjphNzRmMTliZWZkOGM0MTAwOTI4ZGNhZTQ4MDRmYTZjYl8xMTg3_a50263e6-3d51-4d4b-a083-29a8584b3b28">276-2000</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> (Former Name or Former Address, if Changed Since Last Report.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:13.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> General Instruction A.2.):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6MzI3NzUxOGM5NTJjNDMxZjk1OTQ2YTY4ZmQxYThiMzIvdGFibGVyYW5nZTozMjc3NTE4Yzk1MmM0MzFmOTU5NDZhNjhmZDFhOGIzMl8wLTAtMS0xLTE5NzIwNA_f7fa0b97-e52e-4fa8-9c56-f8cc997b0243">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.130%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6MDgwMzI5OTg5MjRmNGUxOGFjOTYxZjRjZWZjNmQ1ZmEvdGFibGVyYW5nZTowODAzMjk5ODkyNGY0ZTE4YWM5NjFmNGNlZmM2ZDVmYV8wLTAtMS0xLTE5NzIwNA_4b3861dd-597f-4c2e-a855-55d25cbf71b5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6MGNkMmE3NGU4NjdiNDViYzgzYmFmNzI5MmU4NWI4YjUvdGFibGVyYW5nZTowY2QyYTc0ZTg2N2I0NWJjODNiYWY3MjkyZTg1YjhiNV8wLTAtMS0xLTE5NzIwNA_7841b994-06ce-469d-bf30-1f6faf7e4596">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:2.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6OWQ5YmY2ZDRhZjgwNDFmZmIwNjFjMDA3Mjc4MTczYWEvdGFibGVyYW5nZTo5ZDliZjZkNGFmODA0MWZmYjA2MWMwMDcyNzgxNzNhYV8wLTAtMS0xLTE5NzIwNA_4d114017-84df-4127-8d84-804633a8c83e">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:1pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if99194a62558408da3eaf072492056d6_D20230202-20230202" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8xLTAtMS0xLTE5NzIwNA_9632c50e-ba9b-4d16-a6cd-0f6c2af91dbb">Common Stock (no par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if99194a62558408da3eaf072492056d6_D20230202-20230202" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8xLTItMS0xLTE5NzIwNA_40e70fe2-f2c3-4451-b3af-e9a7a405cc39">LLY</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if99194a62558408da3eaf072492056d6_D20230202-20230202" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8xLTQtMS0xLTE5NzIwNA_bf4ca8f5-7453-4e67-9948-6d5d41c1d0b5">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i66c6ae2792ff4b84a5ebbb81244eb4b3_D20230202-20230202" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8yLTAtMS0xLTE5NzIwNA_9d09c346-5e31-4acc-a475-a31869d86748">7 1/8% Notes due 2025</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i66c6ae2792ff4b84a5ebbb81244eb4b3_D20230202-20230202" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8yLTItMS0xLTE5NzIwNA_a213c462-bb80-4fd7-8e38-36907794ba1f">LLY25</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i66c6ae2792ff4b84a5ebbb81244eb4b3_D20230202-20230202" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8yLTQtMS0xLTE5NzIwNA_626bb3dd-9ffb-4b14-96bf-d26a66b297b8">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i92c908dd435545b08496ae4273d1083b_D20230202-20230202" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8zLTAtMS0xLTE5NzIwNA_fe6d812b-a875-4b6d-a49d-a0a270cdd371">1.625% Notes due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i92c908dd435545b08496ae4273d1083b_D20230202-20230202" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8zLTItMS0xLTE5NzIwNA_afae0a1d-a87b-474e-8515-892411e8de33">LLY26</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i92c908dd435545b08496ae4273d1083b_D20230202-20230202" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8zLTQtMS0xLTE5NzIwNA_5b6f2e13-66a5-4ea4-8af3-7d9417f5e7be">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c813e1023704a5987a3b758b72289a4_D20230202-20230202" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF80LTAtMS0xLTE5NzIwNA_0d6d33c5-f1ff-4b25-986d-72f8b0b9bc4e">2.125% Notes due 2030</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c813e1023704a5987a3b758b72289a4_D20230202-20230202" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF80LTItMS0xLTE5NzIwNA_7e401cfd-f7bd-42ee-bdb1-188a58c2b42c">LLY30</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c813e1023704a5987a3b758b72289a4_D20230202-20230202" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF80LTQtMS0xLTE5NzIwNA_332bd8bf-ab70-4516-bbba-8cca0da17d75">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i26372fc909e145c3b425f3f58cb0c510_D20230202-20230202" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF81LTAtMS0xLTE5NzIwNA_379abb68-db4d-4930-b5ad-991584353ad0">0.625% Notes due 2031</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i26372fc909e145c3b425f3f58cb0c510_D20230202-20230202" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF81LTItMS0xLTE5NzIwNA_1c451bc9-0d6a-46d9-b7f2-9fe26abfff16">LLY31</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i26372fc909e145c3b425f3f58cb0c510_D20230202-20230202" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF81LTQtMS0xLTE5NzIwNA_f5df9dc0-49fc-4c21-a1f3-a48cc7d70069">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2f5b20c214394dc8bc427934d0f5d13b_D20230202-20230202" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF82LTAtMS0xLTE5NzIwNA_20a872c0-958a-4295-ac91-53a2d825dcf4">0.500% Notes due 2033</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2f5b20c214394dc8bc427934d0f5d13b_D20230202-20230202" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF82LTItMS0xLTE5NzIwNA_97d2958a-5764-415e-b632-195f8d8ed4cf">LLY33</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2f5b20c214394dc8bc427934d0f5d13b_D20230202-20230202" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF82LTQtMS0xLTE5NzIwNA_20a0061b-6cbe-4dcf-9a3b-81dc58566768">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i696cdd16d5b148f9b8875c2c416d58e3_D20230202-20230202" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF83LTAtMS0xLTE5NzIwNA_05f2ebdf-b85f-4c2d-a452-de0fb820d4e0">6.77% Notes due 2036</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i696cdd16d5b148f9b8875c2c416d58e3_D20230202-20230202" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF83LTItMS0xLTE5NzIwNA_01ff47f7-0dd7-4835-89b0-a5797fd941c0">LLY36</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i696cdd16d5b148f9b8875c2c416d58e3_D20230202-20230202" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF83LTQtMS0xLTE5NzIwNA_c5fada6a-8704-4503-8e18-df3efa406dd4">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i63b8eaf69bd6416a9096eda3d15fc666_D20230202-20230202" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF84LTAtMS0xLTE5NzIwNA_fa0133b5-7623-46f2-b758-88b3424aa310">1.625% Notes due 2043</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i63b8eaf69bd6416a9096eda3d15fc666_D20230202-20230202" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF84LTItMS0xLTE5NzIwNA_ecbc99e7-bbd7-4c29-98c7-bfd2c8683324">LLY43</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i63b8eaf69bd6416a9096eda3d15fc666_D20230202-20230202" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF84LTQtMS0xLTE5NzIwNA_168e35c3-4645-4071-a278-6372dc34e510">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibaff8c4f2c594068b5d1f826b384e156_D20230202-20230202" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF85LTAtMS0xLTE5NzIwNA_9f6b4906-516f-4ede-8697-64b58fa5c62d">1.700% Notes due 2049</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibaff8c4f2c594068b5d1f826b384e156_D20230202-20230202" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF85LTItMS0xLTE5NzIwNA_792367d6-2ca3-4bdf-949d-37046049062e">LLY49A</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibaff8c4f2c594068b5d1f826b384e156_D20230202-20230202" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF85LTQtMS0xLTE5NzIwNA_59090a7d-f92b-4c59-8755-be91851f0827">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c6077d2ffa84ee1b11a5af3affa1b67_D20230202-20230202" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8xMC0wLTEtMS0xOTcyMDQ_41a1dbfc-9205-47e8-a285-695e4f6bbf75">1.125% Notes due 2051</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c6077d2ffa84ee1b11a5af3affa1b67_D20230202-20230202" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8xMC0yLTEtMS0xOTcyMDQ_ab409ebc-caba-48b2-8812-7d7e9ef19078">LLY51</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c6077d2ffa84ee1b11a5af3affa1b67_D20230202-20230202" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8xMC00LTEtMS0xOTcyMDQ_2ec49999-251d-4ace-ac72-c4c9bb17a500">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i001eb9c620264821a3025473010e03ac_D20230202-20230202" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8xMS0wLTEtMS0xOTcyMDQ_ef8eb516-de1d-4655-8ad2-196d9648f297">1.375% Notes due 2061</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i001eb9c620264821a3025473010e03ac_D20230202-20230202" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8xMS0yLTEtMS0xOTcyMDQ_77b23dfe-44a0-4ebf-ab6b-f145672f0dcf">LLY61</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i001eb9c620264821a3025473010e03ac_D20230202-20230202" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8xMS00LTEtMS0xOTcyMDQ_9bd851f8-9092-48d0-9b9d-799f497dcc9c">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGV4dHJlZ2lvbjphNzRmMTliZWZkOGM0MTAwOTI4ZGNhZTQ4MDRmYTZjYl8xMTg4_204dbe32-5a1b-49f6-9074-68a2ca4b6b54">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i36186d4ec9284ff4a41b89da947a5125_7"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02.  Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated February 2, 2023, announcing the financial results of Eli Lilly and Company for the quarter and year ended December 31, 2022.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9.01.  Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.497%"><tr><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.745%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q422lillysalesandearningsp.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q422lillysalesandearningsp.htm">Press Release of Eli Lilly and Company, dated</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q422lillysalesandearningsp.htm"> February 2,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q422lillysalesandearningsp.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q422lillysalesandearningsp.htm">202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q422lillysalesandearningsp.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q422lillysalesandearningsp.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.707%"><tr><td style="width:1.0%"></td><td style="width:15.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.858%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.666%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ELI LILLY AND COMPANY</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Registrant)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Donald A. Zakrowski</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Donald A. Zakrowski</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Senior Vice President, Finance, and <br/>Chief Accounting Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 2, 2023</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>q422lillysalesandearningsp.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i362dc6613fc343fca1860c8c7da77542_1"></div><div style="min-height:103.68pt;width:100%"><div style="text-align:right"><img alt="logoa31a.jpg" src="logoa31a.jpg" style="height:70px;margin-bottom:5pt;vertical-align:text-bottom;width:112px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Feb. 2, 2023</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:12pt;font-weight:700;line-height:100%">For Release&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Immediately</font></div><div><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Refer to&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Jordan Bishop&#59; jordan.bishop&#64;lilly.com&#59; (317) 473-5712 (Media)</font></div><div style="padding-left:36pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Joe Fletcher&#59; jfletcher&#64;lilly.com&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(317) 296-2884</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%"> (Investors)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:140%">Lilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-Term Outlook</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">Revenue in Q4 2022 decreased 9%. Excluding COVID-19 antibodies, revenue in Q4 2022 increased 5%, or 10% on a constant currency basis, driven by volume growth of key growth products, partially offset by lower Alimta revenue. Excluding COVID-19 antibodies, total worldwide volume in Q4 2022 increased 13%. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#212121;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">Pipeline advancements included FDA approval of Jaypirca for mantle cell lymphoma under the accelerated approval pathway and FDA and EMA acceptance of regulatory submissions for Jardiance for adults with chronic kidney disease. Additionally, the company initiated a rolling submission in the U.S. for tirzepatide in obesity and the FDA granted Fast Track designation for tirzepatide in obstructive sleep apnea.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">Key growth products - consisting of Verzenio, Mounjaro, Jardiance, Taltz, Trulicity, Retevmo, Emgality, Cyramza, Tyvyt and Olumiant - grew 21% and represented 70% of revenue in Q4 2022.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">Q4 2022 EPS increased 13% to $2.14 on a reported basis and decreased 4% to $2.09 on a non-GAAP basis, both inclusive of $0.23 of acquired IPR&#38;D and development milestone charges. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">2023</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> EPS guidance updated to be in the range of $7.90 to $8.10 on a reported basis and $8.35 to $8.55 on a non-GAAP basis.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">INDIANAPOLIS, Feb. 2, 2023 - Eli Lilly and Company (NYSE&#58; LLY) today announced its financial results for the fourth quarter of 2022.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#34;2023 is an inflection point for Lilly - a chance to expand our impact on patients and growth potential as an R&#38;D-driven biopharma company,&#34; said David A. Ricks, Lilly's chair and CEO. &#34;Over the course of this critical year, we hope to launch as many as four new medicines for challenging diseases, while advancing our next generation of molecules currently in Phase 3.&#34;</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Eli Lilly and Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#124; Lilly Corporate Center &#124; Indianapolis, Indiana 46285 &#124; U.S.A.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Anat Ashkenazi, Lilly's executive vice president and chief financial officer added&#58; &#34;As we closed out 2022, Lilly demonstrated strong growth and achieved meaningful pipeline progress that included the launch for Mounjaro in type 2 diabetes. We expect to capitalize on this momentum and deliver mid-teen revenue growth for our core business in 2023 while remaining committed to investing in innovation, late-stage opportunities, manufacturing capacity, and our people.&#34; </font></div><div id="i362dc6613fc343fca1860c8c7da77542_4"></div><div><font style="color:#242424;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> </font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Lilly shared numerous updates recently on key regulatory, clinical, business development and other events, including&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:180%">&#8226;</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The U.S. Food and Drug Administration (FDA) approval of Jaypirca</font><font style="color:#212121;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:180%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> (pirtobrutinib) for adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a BTK inhibitor, under the accelerated approval pathway&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:180%">&#8226;</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">FDA issuance of a complete response letter for the accelerated approval submission of donanemab for early Alzheimer's disease&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:180%">&#8226;</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">FDA and European Medicines Agency acceptance of regulatory submissions for Jardiance</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> for adults with chronic kidney disease based on results from the EMPA-KIDNEY Phase 3 trial&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#212121;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:14.15pt">The initiation of a rolling submission in the U.S. for tirzepatide in obesity and FDA Fast Track designation for tirzepatide in obstructive sleep apnea&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The announcement that Jardiance is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">Positive donanemab data from the first Phase 3 active comparator study in early Alzheimer's disease, TRAILBLAZER-ALZ 4&#59;  </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">Plans to invest an additional $450 million and create at least 100 new jobs to expand manufacturing capacity at the company's Research Triangle Park facility&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="background-color:#ffffff;color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The acquisition of Akouos, Inc., which expands Lilly's efforts in genetic medicines to include Akouos's potential first-in-class adeno-associated viral gene therapies&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="background-color:#ffffff;color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The fifth consecutive 15% annual increase in Lilly's quarterly dividend, doubling since 2018&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="background-color:#ffffff;color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">A collaboration with EVA Pharma to establish local manufacturing capabilities to supply low-cost insulin to at least 1 million people by 2030, mostly in Africa&#59; and</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;2</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="background-color:#ffffff;color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">An initiative with Direct Relief to expand cold chain capacity in Africa, Latin America, the Caribbean and Southeast Asia.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For additional information on these and other important public announcements, visit the news section of Lilly's website.</font></div><div><font><br></font></div><div id="i362dc6613fc343fca1860c8c7da77542_7"></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Financial Results</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.660%"><tr><td style="width:1.0%"></td><td style="width:46.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.901%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.901%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.904%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$ in millions, except <br>per share data</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Fourth Quarter</font></div></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">2021</font></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Change</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">$7,301.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">$7,999.9</font></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">(9)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">Net Income &#8211; Reported</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1,937.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1,726.1</font></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">12%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">EPS &#8211; Reported</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">2.14</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1.90</font></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">13%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">Net Income &#8211; Non-GAAP</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1,893.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1,970.5</font></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">(4)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">EPS &#8211; Non-GAAP</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">2.09</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">2.17</font></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">(4)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt"><font><br></font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">A discussion of the non-GAAP financial measures is included under &#34;Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited).&#34;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Fourth-Quarter Reported Results</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In Q4 2022, worldwide revenue was $7.30 billion, a decrease of 9% compared with Q4 2021, driven by a 4% decrease from the unfavorable impact of foreign exchange rates, a 3% decrease due to lower realized prices, and a 2% decrease in volume. Excluding COVID-19 antibodies, revenue in Q4 2022 increased 5% and total worldwide volume increased 13%. Key growth products, consisting of Verzenio</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Mounjaro</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Jardiance, Taltz</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Trulicity</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Retevmo</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Emgality</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Cyramza</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Tyvyt</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> and Olumiant</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, grew 21% and represented 70% of revenue for Q4 2022.</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;3</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Revenue in the U.S. decreased 10% to $4.66 billion, driven by a 10% decrease in volume with prices remaining relatively flat. Excluding revenue from COVID-19 antibodies, revenue in the U.S. increased by 11%, primarily driven by volume from key growth products. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Revenue outside the U.S. decreased 6% to $2.64 billion, driven by a 12% decrease from the unfavorable impact of foreign exchange rates and a 7% decrease due to lower realized prices, partially offset by a 12% increase in volume. The lower realized prices were primarily driven by the impact of government pricing in China from the volume-based procurement (VBP) for Humalog</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> and the National Reimbursement Drug List (NRDL) formulary for certain products, particularly Verzenio and Tyvyt. The increase in volume outside the U.S. was largely driven by key growth products and approximately $130 million of one-time revenue associated with the sale of the company's rights to Alimta in Korea and Taiwan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Gross margin decreased 3% to $5.75 billion in Q4 2022 compared with Q4 2021. Gross margin as a percent of revenue was 78.8%, an increase of 4.4 percentage points compared with Q4 2021. The increase in gross margin percent was primarily driven by lower sales of COVID-19 antibodies, partially offset by lower realized prices and increased expenses due to inflation and logistics costs.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In Q4 2022, research and development expenses increased 5% to $2.00 billion, or 27% of revenue, driven by higher development expenses for late-stage assets, partially offset by the favorable impact of foreign exchange rates and lower development expenses for COVID-19 antibodies.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Marketing, selling and administrative expenses increased 3% to $1.64 billion in Q4 2022, primarily driven by costs associated with launches of new products and indications, partially offset by the favorable impact of foreign exchange rates. </font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;4</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In Q4 2022, the company recognized acquired in-process research and development (IPR&#38;D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">and development milestone charges of $240.1 million. In Q4 2021, the company recognized acquired IPR&#38;D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">and development milestone charges of $437.7 million, primarily related to a business development transaction with Foghorn Therapeutics Inc.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In Q4 2022, the company recognized asset impairment, restructuring and other special charges of $38.1 million, primarily related to acquisition and integration costs associated with the closing of our acquisition of Akouos, Inc. In Q4 2021, the company recognized asset impairment, restructuring and other special charges of $104.5 million, primarily related to impairment of an intangible asset from our acquisition of Loxo Oncology.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Operating income in Q4 2022 was $1.84 billion compared with</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> $1.92 billion i</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">n Q4 2021. Operating margin percent, defined as operating income as a percent of revenue, was 25.1%, which includes a negative impact of approximately 330 basis points attributed to acquired IPR&#38;D and development milestone charges.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Other income (expense) was income of $260.0 million in Q4 2022 compared with expense of $77.3 million in Q4 2021. The increase in other income (expense) was primarily driven by net gains on investments in equity securities in Q4 2022 compared with net losses on investments in equity securities in Q4 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The effective tax rate was 7.6% in Q4 2022 compared with 6.2% in Q4 2021. The effective tax rate in Q4 2022 reflects the favorable tax impact of the implementation of the provision in the Tax Cuts and Jobs Act (the 2017 Tax Act) that requires capitalization and amortization of research and development expenses for tax purposes starting in 2022 and a net discrete tax benefit, partially offset by the tax impact of the mix of earnings in higher tax jurisdictions. The effective tax rate in Q4 2021 reflected a net discrete tax benefit and the tax impact of acquired IPR&#38;D and development milestone charges.</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;5</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In Q4 2022, net income and earnings per share (EPS) were $1.94 billion and $2.14, respectively, compared with $1.73&#160;billion and $1.90 in Q4 2021. Q4 2022 EPS was </font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">inclusive of </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">$0.23</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> of acquired IPR&#38;D and development milestone charges compared with </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">$0.39</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> in </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Q4</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">2021</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">.</font></div><div><font><br></font></div><div id="i362dc6613fc343fca1860c8c7da77542_10"></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Fourth-Quarter Non-GAAP Measures</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">On a non-GAAP basis, Q4 2022 gross margin decreased 3% to $5.88 billion compared with Q4 2021. Gross margin as a percent of revenue was 80.5%, an increase of 4.4 percentage points compared with Q4 2021. The increase in gross margin percent was primarily driven by lower sales of COVID-19 antibodies, partially offset by lower realized prices and increased expenses due to inflation and logistics costs.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Operating income on a non-GAAP basis decreased $160.5 million, or 7%, to $2.00 billion in Q4 2022 compared with Q4 2021. Operating margin percent was 27.4% on a non-GAAP basis, which includes a negative impact of approximately 330 basis points attributed to acquired IPR&#38;D and development milestone charges.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The effective tax rate on a non-GAAP basis was 7.3% in Q4 2022 compared with 8.5% in Q4 2021. The lower effective tax rate for Q4 2022 reflects the favorable tax impact of the implementation of the 2017 Tax Act and a higher net discrete tax benefit compared to the same period in 2021, partially offset by the tax impact of the mix of earnings in higher tax jurisdictions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">On a non-GAAP basis, Q4 2022 net income and EPS were $1.89 billion and $2.09, respectively, compared with $1.97 billion and $2.17 in Q4 2021. Q4 2022 non-GAAP EPS was </font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">inclusive of </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">$0.23</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> of acquired IPR&#38;D and development milestone charges compared with </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">$0.39</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> in </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Q4</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">2021</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">.</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;6</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For further detail on non-GAAP measures, see the reconciliation below as well as the &#34;Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)&#34; table later in this press release.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="12" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Fourth Quarter</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2021</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">% Change</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (reported)</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">2.14</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">1.90</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">13%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Amortization of intangible assets</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Asset impairment, restructuring and other special charges</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.03&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.09&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Net (gains) losses on investments in equity securities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(.19)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.06&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Partial reversal of COVID-19 antibodies inventory charges</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(.07)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (non-GAAP)</font></div></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">2.09</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">2.17</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">(4)%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">Numbers may not add due to rounding.</font></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Acquired IPR&#38;D and development milestone charges</font></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.23&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.39&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(41)%</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;7</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="i362dc6613fc343fca1860c8c7da77542_22"></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Selected Revenue Highlights</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.277%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.277%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.277%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.277%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.227%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:18pt"><td colspan="6" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:180%">(Dollars in millions)</font></div></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Fourth Quarter</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Full Year</font></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Selected Products</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">% Change</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">% Change</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Trulicity</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,936.2&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,883.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">3%</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">7,439.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">6,471.9&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">15%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Verzenio</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">808.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">404.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2,483.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,349.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">84%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Taltz</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">707.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">647.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">9%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2,482.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2,212.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">12%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Jardiance</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(a)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">612.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">431.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">42%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2,066.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,490.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">39%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Humalog</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">548.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">601.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(9)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2,060.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2,453.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(16)%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">COVID-19 antibodies</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(c)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">38.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,063.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(96)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2,023.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2,239.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(10)%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Humulin</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">234.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">298.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(22)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,019.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,222.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(17)%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Cyramza</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">277.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">270.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">3%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">971.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,033.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(6)%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Alimta</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">236.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">434.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(46)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">927.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2,061.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(55)%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Olumiant</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(d)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">205.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">306.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(33)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">830.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,115.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(26)%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Basaglar</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">201.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">242.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(17)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">760.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">892.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(15)%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Emgality</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">175.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">161.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">9%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">650.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">577.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">13%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Forteo</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">160.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">184.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(13)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">613.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">801.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(24)%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Mounjaro</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">279.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">482.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Tyvyt</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">57.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">77.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(26)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">293.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">418.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(30)%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Retevmo</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">64.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">38.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">67%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">191.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">114.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">67%</font></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Total Revenue</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">7,301.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">7,999.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(9)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">28,541.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">28,318.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1%</font></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="36" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> Jardiance includes Glyxambi</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">, Synjardy</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> and Trijardy</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> XR</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> Humalog includes Insulin Lispro</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab, and were made pursuant to EUAs or similar regulatory authorizations </font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> Olumiant includes sales</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">baricitinib that were made pursuant to EUA or similar regulatory authorizations</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">NM &#8211; not meaningful</font></div></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;8</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Trulicity</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q4 2022, worldwide Trulicity revenue was $1.94 billion, an increase of 3% compared with Q4 2021. U.S. revenue increased 5% to $1.53 billion, driven by increased demand, partially offset by lower realized prices. Revenue outside the U.S. was $409.8 million, a decrease of 6%, driven by the unfavorable impact of foreign exchange rates and to a lesser extent, lower realized prices, partially offset by increased demand. On a constant currency basis, revenue outside the U.S. increased 8%. Lilly experienced intermittent delays in fulfilling certain U.S. Trulicity orders during Q4 2022. Actions to manage strong demand across the company's incretin portfolio, including measures to minimize existing patient impact in international markets, also affected volume.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Verzenio</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q4 2022, worldwide Verzenio revenue increased 100% compared with Q4 2021 to $808.0 million. U.S. revenue was $552.7 million, an increase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">of 119%, primarily driven by increased demand. Revenue outside the U.S. was $255.3 million, an increase of 69%, driven by increased demand, partially offset by the unfavorable impact of foreign exchange rates and lower realized prices primarily due to the impact of the NRDL formulary in China.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Taltz</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q4 2022, worldwide Taltz revenue increased 9% compared with Q4 2021 to $707.8&#160;million. U.S. revenue increased 9% to $512.0&#160;million, driven by increased demand, partially offset by lower realized prices. Revenue outside the U.S. increased 11%</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">to $195.8 million, driven by increased volume, partially offset by the unfavorable impact of foreign exchange rates and lower realized prices.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Jardiance</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The company's worldwide Jardiance revenue for Q4 2022 was $612.3 million, an increase of 42% compared with Q4 2021. U.S. revenue increased 51% to $363.1 million, primarily driven by increased demand and to a lesser extent, an increased Q4 2022 royalty from Boehringer Ingelheim for exceeding certain annual thresholds. Revenue outside the U.S. was $249.2 million, an increase of </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;9</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">30%, primarily driven by increased demand, partially offset by the unfavorable impact of foreign exchange rates. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Jardiance is part of the company's alliance with Boehringer Ingelheim. Lilly reports as revenue royalties received on net sales of Jardiance.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Humalog</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q4 2022, worldwide Humalog revenue decreased 9% compared with Q4 2021 to $548.3 million. U.S. revenue increased 8% to $336.0 million, driven by higher realized prices due to changes in estimates for rebates and discounts in both periods. Revenue outside the U.S. decreased 27% to $212.3 million, driven by lower realized prices due to the impact of VBP in China and the unfavorable impact of foreign exchange rates.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Alimta</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q4 2022, worldwide Alimta revenue decreased 46% compared with Q4 2021 to $236.6 million. U.S. revenue decreased 83% to $53.2&#160;million, driven by decreased demand due to generic competition. Revenue outside the U.S. increased 63% to $183.4 million, driven by approximately $130 million of one-time revenue associated with the sale of the company's rights to Alimta in Korea and Taiwan, partially offset by decreased demand due to generic competition, lower realized prices, and the unfavorable impact of foreign exchange rates.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The company expects continued volume and revenue decline for Alimta as a result of generic competition due to the loss of patent exclusivity in major markets. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Olumiant</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q4 2022, worldwide Olumiant revenue decreased 33% compared with Q4 2021 to $205.8 million. U.S. revenue decreased 50% to $43.5 million, driven by a decline in utilization for COVID-19 treatment, partially offset by increased utilization for the treatment of alopecia areata. </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;10</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Revenue outside the U.S. was $162.3 million, a decrease of 26%, driven by the unfavorable impact of foreign exchange rates and a decline in utilization for COVID-19 treatment.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Emgality</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q4 2022, Emgality generated worldwide revenue of $175.6 million, an increase of 9% compared with Q4 2021. U.S. revenue was $132.0 million, an increase of 9%, driven by increased demand and higher realized prices, partially offset by wholesaler buying patterns. Revenue outside the U.S. was $43.7 million, an increase of 8%, primarily driven by increased volume, partially offset by the unfavorable impact of foreign exchange rates and lower realized prices. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Mounjaro</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q4 2022, worldwide Mounjaro revenue was $279.2 million. U.S. revenue was $256.7 million. Mounjaro launched in the U.S. for the treatment of type 2 diabetes in June 2022.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Tyvyt</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q4 2022, the company's Tyvyt revenue in China was $57.5 million, a decrease of 26% compared with Q4 2021, driven by the impact of the NRDL formulary in China as well as increased competitive pressures and impacts from COVID-19 disruptions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Tyvyt is part of the company's alliance with Innovent. Lilly reports total sales of Tyvyt made by Lilly as revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales. Lilly also reports as revenue a portion of the gross margin for Tyvyt sales made by Innovent.&#160;</font></div><div><font><br></font></div><div id="i362dc6613fc343fca1860c8c7da77542_28"></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">2023 Financial Guidance </font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:174%">The company has updated its tax rate and EPS guidance and reaffirmed all other elements of its 2023 financial guidance. The previous tax rate guidance of approximately 16% for 2023 assumed deferral or repeal of the 2017 Tax Act provision that requires capitalization of research and development expenses. Such a deferral or repeal did not occur in 2022. Given the uncertainty as to whether any change to this provision will be enacted in 2023, the company has updated the tax rate </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;11</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:174%">guidance to be approximately 13% and 2023 EPS guidance has been increased to the range of $7.90 to $8.10 on a reported basis and $8.35 to $8.55 on a non-GAAP basis. The company's 2023 financial guidance reflects adjustments shown in the reconciliation table below.  </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.685%"><tr><td style="width:1.0%"></td><td style="width:75.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">2023<br>Expectations</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (reported)</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$7.90 to $8.10</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.45</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (non-GAAP)</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$8.35 to $8.55</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:140%">Numbers may not add due to rounding</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">The company's 2023 financial guidance does not include any acquired IPR&#38;D and development milestone charges either incurred or that may potentially be incurred in 2023.</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The following table summarizes the company's updated 2023 financial guidance&#58; </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:44.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.226%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">2023 Guidance</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Prior</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Updated</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$30.3 to $30.8 billion</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Gross Margin % of Revenue (reported)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 77%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Gross Margin % of Revenue (non-GAAP)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 79%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Marketing, Selling &#38; Administrative</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$6.9 to $7.1 billion</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Research &#38; Development</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$8.2 to $8.4 billion</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Other Income&#47;(Expense)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$(200) to $(100) million</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Tax Rate</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 16%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 13%</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Earnings per Share (reported)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$7.65 to $7.85</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$7.90 to $8.10</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Earnings per Share (non-GAAP)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$8.10 to $8.30</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$8.35 to $8.55</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Non-GAAP guidance reflects adjustments presented in the earnings per share table above.</font></td></tr></table></div><div style="margin-top:5pt"><font><br></font></div><div style="margin-top:5pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;12</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="i362dc6613fc343fca1860c8c7da77542_31"></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:180%">Webcast of Conference Call</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">As previously announced, investors and the general public can access a live webcast of the Q4 2022 financial results conference call through a link on Lilly's website at investor.lilly.com&#47;webcasts-and-presentations. The conference call will begin at 10 a.m. Eastern time today and will be available for replay via the website.</font></div><div><font><br></font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:180%">Non-GAAP Financial Measures</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Certain financial information for 2022 and 2021 is presented on both a reported and a non-GAAP basis. Some numbers in this press release may not add due to rounding. Reported results were prepared in accordance with U.S. generally accepted accounting principles (GAAP) and include all revenue and expenses recognized during the periods. Non-GAAP measures reflect adjustments for the items described in the reconciliation tables later in the release. This press release and related materials provide certain GAAP and non-GAAP figures excluding the impact of foreign exchange rates. Lilly recalculates current period figures on a constant currency basis by keeping constant the exchange rates from the base period. Beginning in 2022, presentations of non-GAAP financial measures do not include adjustments for upfront charges and development milestones related to acquired IPR&#38;D. Non-GAAP financial measures for Q4 and fiscal year 2021 have been adjusted to reflect this updated presentation. The company's 2023 financial guidance is being provided on both a reported and a non-GAAP basis. The non-GAAP measures are presented to provide additional insights into the underlying trends in the company's business.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:180%">About Lilly</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47</font><font style="color:#4472c4;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;13</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing&#58; making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Lilly.com and Lilly.com&#47;newsroom.</font><font style="color:#1f497d;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">F-LLY</font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Statement Regarding Forward-Looking Statements</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains management's current intentions and expectations for the future, all of which are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words &#34;estimate&#34;, &#34;project&#34;, &#34;intend&#34;, &#34;expect&#34;, &#34;believe&#34;, &#34;target&#34;, &#34;anticipate&#34; and similar expressions are intended to identify forward-looking statements. Actual results may differ materially due to various factors. The following include some but not all of the factors that could cause actual results or events to differ materially from those anticipated, including the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals&#59; the impact and outcome of acquisitions and business development transactions and related integration costs&#59; the expiration of intellectual property protection for certain of the company's products and competition from generic and&#47;or biosimilar products&#59; the company's ability to protect and enforce patents and other intellectual property&#59; changes in patent law or regulations related to data package exclusivity&#59; competitive developments affecting current products and the company's pipeline&#59; market uptake of recently launched products&#59; information technology system inadequacies, breaches, or operating failures&#59; unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in the company's information technology systems, networks, and facilities, or those of third parties with whom the company shares its data&#59; the impact of global macroeconomic conditions, trade disruptions, disputes, unrest, war, regional dependencies, or other costs, uncertainties and risks related to engaging in business globally&#59; unexpected safety or efficacy concerns associated with the company's products&#59; litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as the company is largely self-insured&#59; issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, or regulatory actions related to our facilities&#59; dependence on certain products for a significant percentage of our total revenue&#59; reliance on third-party relationships and outsourcing arrangements&#59; the impact of public health outbreaks, epidemics, or pandemics, such as the COVID-19 pandemic&#59; regulatory changes or other developments&#59; regulatory actions regarding operations and products&#59; continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals&#59; devaluations in foreign currency exchange rates or changes in interest rates and inflation&#59; changes in tax law, tax rates, or events that differ from the company's assumptions related to tax positions&#59; asset impairments and restructuring charges&#59; changes in accounting and reporting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC)&#59; regulatory compliance problems or government investigations&#59; and actual or perceived deviation from environmental-, social-, or governance-related requirements or expectations. For additional information about the factors that could cause actual results or events to differ materially from forward-looking statements, please see the company's latest Form 10-K and subsequent Forms 8-K and 10-Q filed with the SEC. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release. Except as is required by law, the company expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this release.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;#&#160;&#160;&#160;&#160;#&#160;&#160;&#160;&#160;#</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;14</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Alimta</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (pemetrexed disodium, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Basaglar</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (insulin glargine injection, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Cyramza</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (ramucirumab, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Emgality</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (galcanezumab-gnlm, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Forteo</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (teriparatide of recombinant DNA origin injection, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Glyxambi</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (empagliflozin&#47;linagliptin, Boehringer Ingelheim)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Humalog</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (insulin lispro injection of recombinant DNA origin, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Humulin</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (human insulin of recombinant DNA origin, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Jardiance</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(empagliflozin, Boehringer Ingelheim)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Jaypirca</font><font style="color:#000000;font-family:'Garamond',serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (pirtobrutinib, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Mounjaro</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (tirzepatide injection, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Olumiant</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (baricitinib, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Qbrexza</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (glycopyrronium cloth, Dermira)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Retevmo</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (selpercatinib, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Synjardy</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (empagliflozin&#47;metformin, Boehringer Ingelheim)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Taltz</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(ixekizumab, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Trijardy</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> XR (empagliflozin&#47;linagliptin&#47;metformin hydrochloride extended release tablets, Boehringer Ingelheim)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Trulicity</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(dulaglutide, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Tyvyt</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (sintilimab injection, Innovent)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Verzenio</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (abemaciclib, Lilly)</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Third party trademarks used herein are trademarks of their respective owners.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;15</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="i362dc6613fc343fca1860c8c7da77542_34"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Operating Results (Unaudited) &#8211; REPORTED</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:31.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.743%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Twelve Months Ended</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">% Chg.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">% Chg.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">7,301.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">7,999.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(9)%</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">28,541.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">28,318.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,548.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2,050.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(24)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6,629.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">7,312.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(9)%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,995.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,898.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">5%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">7,190.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6,930.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">4%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Marketing, selling and administrative</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,643.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,592.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">3%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6,440.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6,431.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&#38;D and development milestones</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">240.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">437.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(45)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">908.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">970.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(6)%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">38.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">104.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(64)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">244.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">316.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(23)%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,836.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,917.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(4)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">7,127.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6,357.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">12%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net interest income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(58.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(74.0)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(268.8)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(314.4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net other income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">318.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(52.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">112.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">260.0&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(77.3)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(320.9)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(201.6)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">59%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2,096.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,839.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">14%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6,806.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6,155.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">11%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">158.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">113.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">39%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">561.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">573.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(2)%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,937.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,726.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">12%</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6,244.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">5,581.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">12%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2.14&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1.90&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">13%</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6.90&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6.12&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">13%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid per share</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">.98&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">.85&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">15%</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">3.92&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">15%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font><br></font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding (thousands) - diluted</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">904,732&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">909,555&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">904,619&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">911,681&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">NM &#8211; not meaningful</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;16</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="i362dc6613fc343fca1860c8c7da77542_37"></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.685%"><tr><td style="width:1.0%"></td><td style="width:21.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.363%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.370%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="33" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;31, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;31, 2021</font></div></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">GAAP Reported</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP Adjusted</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">GAAP Reported</font></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP Adjusted</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font></div></td></tr><tr style="height:8pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1,548.1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(124.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,424.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">2,050.2</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(137.4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,912.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">38.1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(38.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">104.5</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(104.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:9.5pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">260.0</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(216.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">43.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(77.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">70.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">158.7</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(9.7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">149.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">113.8</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">68.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">181.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1,937.7</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(44.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,893.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1,726.1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">244.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,970.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">2.14</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2.09&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1.90</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.27&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2.17&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">The table above reflects only line items with non-GAAP adjustments.&#160;</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.12pt">The company uses non-GAAP financial measures that differ from financial statements reported in conformity with U.S. generally accepted accounting principles (GAAP). The company's non-GAAP measures adjust reported results to exclude amortization of intangibles and other items that are typically highly variable, difficult to predict, and of a size that could have a substantial impact on the company's reported operations for a period. The company believes that these non-GAAP measures provide useful information to investors. Among other things, they may help investors evaluate the company's ongoing operations. They can also assist in making meaningful period-over-period comparisons and in identifying operating trends that would otherwise be masked or distorted by the items subject to the adjustments. Management uses these non-GAAP measures internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. Investors should consider these non-GAAP measures in addition to, not as a substitute for or superior to, measures of financial performance prepared in accordance with GAAP.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;17</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.08pt">Adjustments to certain GAAP reported measures for the three months ended December&#160;31, 2022, include the following&#58; </font></div><div style="margin-bottom:3pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.452%"><tr><td style="width:1.0%"></td><td style="width:39.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.865%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.865%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.865%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(ii)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other specified items</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(iii)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(124.1)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(124.1)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(38.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(38.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(216.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(216.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">25.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(43.7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(9.7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">98.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(172.8)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">29.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(44.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.03&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(0.05)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The table above reflects only line items with non-GAAP adjustments.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-22.47pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-24.76pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude net gains on investments in equity securities.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-27.05pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude primarily the asset impairment, restructuring and other special charges primarily related to acquisition and integration costs associated with closing of the acquisition of Akouos, Inc.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:3pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;18</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.02pt">Adjustments to certain GAAP reported measures for the three months ended December&#160;31, 2021, include the following&#58;</font></div><div style="margin-bottom:3pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.452%"><tr><td style="width:1.0%"></td><td style="width:39.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.865%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization </font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(ii)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other specified items</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(iii)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></div></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(219.9)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">82.5&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(137.4)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(104.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(104.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">70.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">70.6</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">46.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">68.1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">173.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">56.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">244.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.06&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">0.27</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The table above reflects only line items with non-GAAP adjustments.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-22.47pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-24.76pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> net losses</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> on investments in equity securities. </font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-27.05pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude partial reversal of COVID-19 antibodies inventory charge and asset impairment, restructuring and other special charges primarily related to the impairment of a contract-based intangible asset from our acquisition of Loxo Oncology.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;19</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="i362dc6613fc343fca1860c8c7da77542_40"></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.491%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.341%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="33" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Twelve Months Ended</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;31, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Twelve Months Ended</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;31, 2021</font></div></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">GAAP Reported</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP Adjusted</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">GAAP Reported</font></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP Adjusted</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font></div></td></tr><tr style="height:8pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">6,629.8</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(574.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6,055.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">7,312.8</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(908.8)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6,404.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">244.6</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(244.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">316.1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(316.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:9.5pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(320.9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">385.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">65.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(201.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">227.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">25.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">561.6</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">263.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">824.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">573.8</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">300.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">873.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">6,244.8</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">941.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">7,186.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">5,581.7</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,152.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6,733.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">6.90</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1.04&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">7.94&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">6.12</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1.27&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">7.39&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">The table above reflects only line items with non-GAAP adjustments.</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.12pt">The company uses non-GAAP financial measures that differ from financial statements reported in conformity with U.S. generally accepted accounting principles (GAAP). The company's non-GAAP measures adjust reported results to exclude amortization of intangibles and other items that are typically highly variable, difficult to predict, and of a size that could have a substantial impact on the company's reported operations for a period. The company believes that these non-GAAP measures provide useful information to investors. Among other things, they may help investors evaluate the company's ongoing operations. They can also assist in making meaningful period-over-period comparisons and in identifying operating trends that would otherwise be masked or distorted by the items subject to the adjustments. Management uses these non-GAAP measures internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. Investors should consider these non-GAAP measures in addition to, not as a substitute for or superior to, measures of financial performance prepared in accordance with GAAP. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;20</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.08pt">Adjustments to certain GAAP reported measures for the twelve months ended December&#160;31, 2022, include the following&#58; </font></div><div style="margin-bottom:3pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.452%"><tr><td style="width:1.0%"></td><td style="width:39.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.865%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.865%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(ii)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other specified items</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(iii)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(574.1)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(574.1)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(244.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(244.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">385.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">385.9</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">118.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">85.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">58.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">263.0</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">455.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">300.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">186.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">941.6</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; diluted</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.50&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.33&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1.04</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</font></div><div style="margin-bottom:3pt;padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">The table above reflects only line items with non-GAAP adjustments.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-22.47pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-24.76pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude net losses on investments in equity securities.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-27.05pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude primarily the intangible asset impairment for GBA1 Gene Therapy (PR001) due to changes in estimated launch timing, as well as acquisition and integration costs associated with closing of the acquisition of Akouos, Inc.</font></div><div style="margin-bottom:3pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;21</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.02pt">Adjustments to certain GAAP reported measures for the twelve months ended December&#160;31, 2021, include the following&#58;</font></div><div style="margin-bottom:3pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.452%"><tr><td style="width:1.0%"></td><td style="width:24.070%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.865%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(ii)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of Debt</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(iii)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other specified items</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(iv)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Total </font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(614.9)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(293.9)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(908.8)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(316.1)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(316.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(178.0)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">405.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">227.2</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">127.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(34.4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">85.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">121.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">300.1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">487.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(143.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">320.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">488.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1,152.0</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.53&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.54&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1.27</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The table above reflects only line items with non-GAAP adjustments.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-22.47pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-24.76pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude net gains on investments in equity securities.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-27.05pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude charge related to the repurchase of higher-cost debt.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-27.15pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude COVID-19 antibodies inventory charge and asset impairment, restructuring and other special charges primarily related to an intangible asset impairment resulting from the sale of rights to Qbrexza</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">, the impairment of a contract-based intangible asset from our acquisition of Loxo Oncology, as well as acquisition and integration costs associated with the acquisition of Prevail Therapeutics Inc.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;22</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>lly-20230202.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:98b0e548-4886-4cc8-9807-a05ddcd110df,g:27793b14-51c9-40f9-928d-212481ae66bb-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lly="http://www.lilly.com/20230202" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lilly.com/20230202">
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20230202_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20230202_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20230202_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.lilly.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lly_A1.625NotesDueJune22026Member" abstract="true" name="A1.625NotesDueJune22026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A718NotesDueJune12025Member" abstract="true" name="A718NotesDueJune12025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1375NotesDue2061Member" abstract="true" name="A1375NotesDue2061Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A2.125NotesDueJune32030Member" abstract="true" name="A2.125NotesDueJune32030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A500NotesDue2033Member" abstract="true" name="A500NotesDue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1625NotesDue2043Member" abstract="true" name="A1625NotesDue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1125NotesDue2051Member" abstract="true" name="A1125NotesDue2051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A6.77NotesDueJanuary12036Member" abstract="true" name="A6.77NotesDueJanuary12036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A625Notesdue2031Member" abstract="true" name="A625Notesdue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1.700Notesdue2049Member" abstract="true" name="A1.700Notesdue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>lly-20230202_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:98b0e548-4886-4cc8-9807-a05ddcd110df,g:27793b14-51c9-40f9-928d-212481ae66bb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20230202.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended" id="i4db115a57dd54c8a84c8b141b5ad405e_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d0940a10-bffc-474a-b93a-6bea8e0bf03d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_DocumentType_d0940a10-bffc-474a-b93a-6bea8e0bf03d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_fe27c08b-2502-4e98-b817-3edfc69016cf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_DocumentPeriodEndDate_fe27c08b-2502-4e98-b817-3edfc69016cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_805bb908-605f-497b-82a8-3dbd29915c21" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_805bb908-605f-497b-82a8-3dbd29915c21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_083074a5-8729-427e-8c08-9e290f059de4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_EntityFileNumber_083074a5-8729-427e-8c08-9e290f059de4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c621bc79-cf1b-42b2-b851-5906bab39f37" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_EntityTaxIdentificationNumber_c621bc79-cf1b-42b2-b851-5906bab39f37" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3e7d5c31-3e68-4726-a270-79471d9661cf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_EntityAddressAddressLine1_3e7d5c31-3e68-4726-a270-79471d9661cf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9df57c75-2add-404d-94fa-216657fd78a3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_EntityAddressCityOrTown_9df57c75-2add-404d-94fa-216657fd78a3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c2efbcc2-7827-4c73-8096-a4566103e27d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_EntityAddressStateOrProvince_c2efbcc2-7827-4c73-8096-a4566103e27d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_689226a7-c67b-4a17-ac76-3560a90be4bd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_EntityAddressPostalZipCode_689226a7-c67b-4a17-ac76-3560a90be4bd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_e6e326e6-4394-42e8-bc34-15405d34b553" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_CityAreaCode_e6e326e6-4394-42e8-bc34-15405d34b553" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b936cf33-f3c2-4eef-97de-bd84789a9561" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_LocalPhoneNumber_b936cf33-f3c2-4eef-97de-bd84789a9561" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_7af64221-294a-4509-96b5-8b02a3cb9a7b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_WrittenCommunications_7af64221-294a-4509-96b5-8b02a3cb9a7b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_a201bc26-6f61-439d-8387-095e04678f53" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_SolicitingMaterial_a201bc26-6f61-439d-8387-095e04678f53" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_fa248905-3a6c-4487-9cb5-82827178edb8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_PreCommencementTenderOffer_fa248905-3a6c-4487-9cb5-82827178edb8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_80102d27-cd50-40f7-8aba-0f3d68289aeb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_80102d27-cd50-40f7-8aba-0f3d68289aeb" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_48b1fc36-6b69-4076-8057-5635cd63327c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_EntityEmergingGrowthCompany_48b1fc36-6b69-4076-8057-5635cd63327c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_dac05e03-c38e-469c-bb22-c2e270c62485" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_Security12bTitle_dac05e03-c38e-469c-bb22-c2e270c62485" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_81e42c29-fedf-4c32-be42-84bdda97bad1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_TradingSymbol_81e42c29-fedf-4c32-be42-84bdda97bad1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a0f19538-5414-473c-8a25-84e5b27bad31" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_SecurityExchangeName_a0f19538-5414-473c-8a25-84e5b27bad31" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_223d5575-aa4f-474f-9338-3b953a7e8009" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_EntityRegistrantName_223d5575-aa4f-474f-9338-3b953a7e8009" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f8cab624-b7a0-4d2b-9a57-e2c9df49c110" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_EntityCentralIndexKey_f8cab624-b7a0-4d2b-9a57-e2c9df49c110" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_16884722-34b7-40d1-858c-56081b3d1a7e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_AmendmentFlag_16884722-34b7-40d1-858c-56081b3d1a7e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_842fb53c-e235-453f-90f2-64ec02e31bed" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_DocumentInformationTable_842fb53c-e235-453f-90f2-64ec02e31bed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4df6a4c5-acb3-458d-8474-6263d57c526b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_842fb53c-e235-453f-90f2-64ec02e31bed" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4df6a4c5-acb3-458d-8474-6263d57c526b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4df6a4c5-acb3-458d-8474-6263d57c526b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4df6a4c5-acb3-458d-8474-6263d57c526b" xlink:to="loc_us-gaap_ClassOfStockDomain_4df6a4c5-acb3-458d-8474-6263d57c526b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_61e882cd-6b44-4bee-8d2c-5c2ceeb1aaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4df6a4c5-acb3-458d-8474-6263d57c526b" xlink:to="loc_us-gaap_ClassOfStockDomain_61e882cd-6b44-4bee-8d2c-5c2ceeb1aaf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_1c2643bc-d152-49da-96f0-ece8e4df7a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_61e882cd-6b44-4bee-8d2c-5c2ceeb1aaf0" xlink:to="loc_us-gaap_CommonClassAMember_1c2643bc-d152-49da-96f0-ece8e4df7a5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member_b845a3c6-cc05-4926-ba95-35fe28fbc425" xlink:href="lly-20230202.xsd#lly_A718NotesDueJune12025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_61e882cd-6b44-4bee-8d2c-5c2ceeb1aaf0" xlink:to="loc_lly_A718NotesDueJune12025Member_b845a3c6-cc05-4926-ba95-35fe28fbc425" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member_6875d883-9493-47a7-b3e4-36072c693268" xlink:href="lly-20230202.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_61e882cd-6b44-4bee-8d2c-5c2ceeb1aaf0" xlink:to="loc_lly_A1.625NotesDueJune22026Member_6875d883-9493-47a7-b3e4-36072c693268" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_c232b3ab-f7fa-4e0d-9772-702dd89b4b64" xlink:href="lly-20230202.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_61e882cd-6b44-4bee-8d2c-5c2ceeb1aaf0" xlink:to="loc_lly_A2.125NotesDueJune32030Member_c232b3ab-f7fa-4e0d-9772-702dd89b4b64" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member_0c598f9d-6978-4ab4-b7e8-d81f1e2ee73a" xlink:href="lly-20230202.xsd#lly_A625Notesdue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_61e882cd-6b44-4bee-8d2c-5c2ceeb1aaf0" xlink:to="loc_lly_A625Notesdue2031Member_0c598f9d-6978-4ab4-b7e8-d81f1e2ee73a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_e85421d3-1333-4950-844d-13a1d9bb83e5" xlink:href="lly-20230202.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_61e882cd-6b44-4bee-8d2c-5c2ceeb1aaf0" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_e85421d3-1333-4950-844d-13a1d9bb83e5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member_cefe211d-181d-4463-b309-499de67b1631" xlink:href="lly-20230202.xsd#lly_A1.700Notesdue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_61e882cd-6b44-4bee-8d2c-5c2ceeb1aaf0" xlink:to="loc_lly_A1.700Notesdue2049Member_cefe211d-181d-4463-b309-499de67b1631" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A500NotesDue2033Member_97e4f60a-2a7d-473c-b42c-4cb529f82948" xlink:href="lly-20230202.xsd#lly_A500NotesDue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_61e882cd-6b44-4bee-8d2c-5c2ceeb1aaf0" xlink:to="loc_lly_A500NotesDue2033Member_97e4f60a-2a7d-473c-b42c-4cb529f82948" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_d5535a5a-68b6-4b49-b556-9cf8ad2c403f" xlink:href="lly-20230202.xsd#lly_A1625NotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_61e882cd-6b44-4bee-8d2c-5c2ceeb1aaf0" xlink:to="loc_lly_A1625NotesDue2043Member_d5535a5a-68b6-4b49-b556-9cf8ad2c403f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_81cfac18-fc6b-4b3c-8d8d-24787b1c698f" xlink:href="lly-20230202.xsd#lly_A1125NotesDue2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_61e882cd-6b44-4bee-8d2c-5c2ceeb1aaf0" xlink:to="loc_lly_A1125NotesDue2051Member_81cfac18-fc6b-4b3c-8d8d-24787b1c698f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_8b2dc9d4-4edc-4735-9fb9-1b6adeeeceb0" xlink:href="lly-20230202.xsd#lly_A1375NotesDue2061Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_61e882cd-6b44-4bee-8d2c-5c2ceeb1aaf0" xlink:to="loc_lly_A1375NotesDue2061Member_8b2dc9d4-4edc-4735-9fb9-1b6adeeeceb0" xlink:type="arc" order="10"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>lly-20230202_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:98b0e548-4886-4cc8-9807-a05ddcd110df,g:27793b14-51c9-40f9-928d-212481ae66bb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_031b44f5-27c2-49e2-9f21-38f0408469c4_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_bd4ba161-35dd-4b96-b5f2-8b1c68bece49_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1125NotesDue2051Member_dfe90b73-9131-4897-b447-8708c7166980_terseLabel_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2051</link:label>
    <link:label id="lab_lly_A1125NotesDue2051Member_label_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2051 [Member]</link:label>
    <link:label id="lab_lly_A1125NotesDue2051Member_documentation_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member" xlink:href="lly-20230202.xsd#lly_A1125NotesDue2051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1125NotesDue2051Member" xlink:to="lab_lly_A1125NotesDue2051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1625NotesDue2043Member_140f784b-2853-499e-a3cf-f4dfb1d564e4_terseLabel_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625%&#160;Notes due 2043</link:label>
    <link:label id="lab_lly_A1625NotesDue2043Member_label_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625%&#160;Notes due 2043 [Member]</link:label>
    <link:label id="lab_lly_A1625NotesDue2043Member_documentation_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625%&#160;Notes due 2043</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member" xlink:href="lly-20230202.xsd#lly_A1625NotesDue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1625NotesDue2043Member" xlink:to="lab_lly_A1625NotesDue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_c691c493-0cab-4b5d-8ac6-8d6e8579466e_terseLabel_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes due 2026</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_label_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_documentation_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member" xlink:href="lly-20230202.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.625NotesDueJune22026Member" xlink:to="lab_lly_A1.625NotesDueJune22026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_6ba9bfd4-039a-4ccc-ba38-de7fa6e4a820_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_273409ae-9b4d-4978-97dd-b7f43515f8a1_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_ba7dc2a8-ce5e-4ae7-9771-430240ef4e87_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.700Notesdue2049Member_aec09faa-177d-43cc-987d-6d99c48aa105_terseLabel_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049</link:label>
    <link:label id="lab_lly_A1.700Notesdue2049Member_label_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:label id="lab_lly_A1.700Notesdue2049Member_documentation_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member" xlink:href="lly-20230202.xsd#lly_A1.700Notesdue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.700Notesdue2049Member" xlink:to="lab_lly_A1.700Notesdue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_16f092c1-1963-4e02-888a-9037d1d5a19e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1375NotesDue2061Member_85200041-35d6-4bca-98c5-3df69e0899e0_terseLabel_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2061</link:label>
    <link:label id="lab_lly_A1375NotesDue2061Member_label_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2061 [Member]</link:label>
    <link:label id="lab_lly_A1375NotesDue2061Member_documentation_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2061</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member" xlink:href="lly-20230202.xsd#lly_A1375NotesDue2061Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1375NotesDue2061Member" xlink:to="lab_lly_A1375NotesDue2061Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_da18d0d1-d8f3-44a5-b163-80a90a733d9d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_9f8fb82a-932c-40fa-8bbc-a2572a0b74fc_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_de77d883-8907-4d98-8b30-c05d9a00f005_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_43342b6c-ea03-4173-a0f1-99745c589e1a_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_72340c2b-d400-4914-a1a5-bc5780dbbe3b_terseLabel_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77% Notes due 2036</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_label_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_documentation_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member" xlink:href="lly-20230202.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A6.77NotesDueJanuary12036Member" xlink:to="lab_lly_A6.77NotesDueJanuary12036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A718NotesDueJune12025Member_235ff1a7-97f9-42ef-bfe6-0cab8cd819da_terseLabel_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes due 2025</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_label_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes Due June&#160;1, 2025 [Member]</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_documentation_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes Due June&#160;1, 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member" xlink:href="lly-20230202.xsd#lly_A718NotesDueJune12025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A718NotesDueJune12025Member" xlink:to="lab_lly_A718NotesDueJune12025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_dce5c1ea-5dd3-4a4b-bd10-ce7decf74d73_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_348f184d-3b9b-4fea-92b9-6d9e31f00302_terseLabel_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes due 2030</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_label_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_documentation_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member" xlink:href="lly-20230202.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A2.125NotesDueJune32030Member" xlink:to="lab_lly_A2.125NotesDueJune32030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_3fcb9075-cc90-4a72-9baf-7ca773166db0_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_0cb7b2ac-21a6-4561-949a-4eecdd346fa7_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_1195fd6d-6461-4f0c-a88d-ad9f4a9f0fb0_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ba375c2c-5ae1-4af9-9e9d-0082f21e769f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A500NotesDue2033Member_31f56ee8-11db-4141-b743-28bcd4733281_terseLabel_en-US" xlink:label="lab_lly_A500NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2033</link:label>
    <link:label id="lab_lly_A500NotesDue2033Member_label_en-US" xlink:label="lab_lly_A500NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.500% Notes due 2033 [Member]</link:label>
    <link:label id="lab_lly_A500NotesDue2033Member_documentation_en-US" xlink:label="lab_lly_A500NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2033</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A500NotesDue2033Member" xlink:href="lly-20230202.xsd#lly_A500NotesDue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A500NotesDue2033Member" xlink:to="lab_lly_A500NotesDue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f652d918-eec1-4c4c-a171-2e5f6099f677_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_fd1b2832-8e55-4108-9a07-d14a4d856098_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_5d570806-4fe3-448d-ad29-cf317b74f4dc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_07456b0b-8d9d-4c60-af74-8ec6c1881f7a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_dcd0e697-7510-4030-86bf-f119de27f710_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_ccf58752-fce4-4d07-a3fc-c013893d9fc7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock (no par value)</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_3eeb09a6-9b22-4f9b-97b7-8982fa6e2801_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_8d27d8b1-d0d6-4802-a2fa-0167328fee49_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A625Notesdue2031Member_b4421277-3785-4036-b499-96cb56e1c571_terseLabel_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.625% Notes due 2031</link:label>
    <link:label id="lab_lly_A625Notesdue2031Member_label_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:label id="lab_lly_A625Notesdue2031Member_documentation_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member" xlink:href="lly-20230202.xsd#lly_A625Notesdue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A625Notesdue2031Member" xlink:to="lab_lly_A625Notesdue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_fa0d3b75-df51-4803-a60f-58a32e72894b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_344d664f-d1d6-4a95-9847-80ff9c5df46f_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_e72ac213-415c-4f8f-a4c5-e531f10740be_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f4377d20-8aeb-431f-a9db-db3790a19d33_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_db98d740-f01e-4166-95e3-1b18202ba409_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>lly-20230202_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:98b0e548-4886-4cc8-9807-a05ddcd110df,g:27793b14-51c9-40f9-928d-212481ae66bb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20230202.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_3dae2b19-cd91-4cd0-95f9-fab9ca1585c8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_842fb53c-e235-453f-90f2-64ec02e31bed" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dae2b19-cd91-4cd0-95f9-fab9ca1585c8" xlink:to="loc_dei_DocumentInformationTable_842fb53c-e235-453f-90f2-64ec02e31bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4df6a4c5-acb3-458d-8474-6263d57c526b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_842fb53c-e235-453f-90f2-64ec02e31bed" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4df6a4c5-acb3-458d-8474-6263d57c526b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_61e882cd-6b44-4bee-8d2c-5c2ceeb1aaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4df6a4c5-acb3-458d-8474-6263d57c526b" xlink:to="loc_us-gaap_ClassOfStockDomain_61e882cd-6b44-4bee-8d2c-5c2ceeb1aaf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_1c2643bc-d152-49da-96f0-ece8e4df7a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_61e882cd-6b44-4bee-8d2c-5c2ceeb1aaf0" xlink:to="loc_us-gaap_CommonClassAMember_1c2643bc-d152-49da-96f0-ece8e4df7a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member_b845a3c6-cc05-4926-ba95-35fe28fbc425" xlink:href="lly-20230202.xsd#lly_A718NotesDueJune12025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_61e882cd-6b44-4bee-8d2c-5c2ceeb1aaf0" xlink:to="loc_lly_A718NotesDueJune12025Member_b845a3c6-cc05-4926-ba95-35fe28fbc425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member_6875d883-9493-47a7-b3e4-36072c693268" xlink:href="lly-20230202.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_61e882cd-6b44-4bee-8d2c-5c2ceeb1aaf0" xlink:to="loc_lly_A1.625NotesDueJune22026Member_6875d883-9493-47a7-b3e4-36072c693268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_c232b3ab-f7fa-4e0d-9772-702dd89b4b64" xlink:href="lly-20230202.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_61e882cd-6b44-4bee-8d2c-5c2ceeb1aaf0" xlink:to="loc_lly_A2.125NotesDueJune32030Member_c232b3ab-f7fa-4e0d-9772-702dd89b4b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member_0c598f9d-6978-4ab4-b7e8-d81f1e2ee73a" xlink:href="lly-20230202.xsd#lly_A625Notesdue2031Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_61e882cd-6b44-4bee-8d2c-5c2ceeb1aaf0" xlink:to="loc_lly_A625Notesdue2031Member_0c598f9d-6978-4ab4-b7e8-d81f1e2ee73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_e85421d3-1333-4950-844d-13a1d9bb83e5" xlink:href="lly-20230202.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_61e882cd-6b44-4bee-8d2c-5c2ceeb1aaf0" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_e85421d3-1333-4950-844d-13a1d9bb83e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member_cefe211d-181d-4463-b309-499de67b1631" xlink:href="lly-20230202.xsd#lly_A1.700Notesdue2049Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_61e882cd-6b44-4bee-8d2c-5c2ceeb1aaf0" xlink:to="loc_lly_A1.700Notesdue2049Member_cefe211d-181d-4463-b309-499de67b1631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A500NotesDue2033Member_97e4f60a-2a7d-473c-b42c-4cb529f82948" xlink:href="lly-20230202.xsd#lly_A500NotesDue2033Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_61e882cd-6b44-4bee-8d2c-5c2ceeb1aaf0" xlink:to="loc_lly_A500NotesDue2033Member_97e4f60a-2a7d-473c-b42c-4cb529f82948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_d5535a5a-68b6-4b49-b556-9cf8ad2c403f" xlink:href="lly-20230202.xsd#lly_A1625NotesDue2043Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_61e882cd-6b44-4bee-8d2c-5c2ceeb1aaf0" xlink:to="loc_lly_A1625NotesDue2043Member_d5535a5a-68b6-4b49-b556-9cf8ad2c403f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_81cfac18-fc6b-4b3c-8d8d-24787b1c698f" xlink:href="lly-20230202.xsd#lly_A1125NotesDue2051Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_61e882cd-6b44-4bee-8d2c-5c2ceeb1aaf0" xlink:to="loc_lly_A1125NotesDue2051Member_81cfac18-fc6b-4b3c-8d8d-24787b1c698f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_8b2dc9d4-4edc-4735-9fb9-1b6adeeeceb0" xlink:href="lly-20230202.xsd#lly_A1375NotesDue2061Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_61e882cd-6b44-4bee-8d2c-5c2ceeb1aaf0" xlink:to="loc_lly_A1375NotesDue2061Member_8b2dc9d4-4edc-4735-9fb9-1b6adeeeceb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_842fb53c-e235-453f-90f2-64ec02e31bed" xlink:to="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d0940a10-bffc-474a-b93a-6bea8e0bf03d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_DocumentType_d0940a10-bffc-474a-b93a-6bea8e0bf03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_fe27c08b-2502-4e98-b817-3edfc69016cf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_DocumentPeriodEndDate_fe27c08b-2502-4e98-b817-3edfc69016cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_805bb908-605f-497b-82a8-3dbd29915c21" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_805bb908-605f-497b-82a8-3dbd29915c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_083074a5-8729-427e-8c08-9e290f059de4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_EntityFileNumber_083074a5-8729-427e-8c08-9e290f059de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c621bc79-cf1b-42b2-b851-5906bab39f37" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_EntityTaxIdentificationNumber_c621bc79-cf1b-42b2-b851-5906bab39f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3e7d5c31-3e68-4726-a270-79471d9661cf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_EntityAddressAddressLine1_3e7d5c31-3e68-4726-a270-79471d9661cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9df57c75-2add-404d-94fa-216657fd78a3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_EntityAddressCityOrTown_9df57c75-2add-404d-94fa-216657fd78a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c2efbcc2-7827-4c73-8096-a4566103e27d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_EntityAddressStateOrProvince_c2efbcc2-7827-4c73-8096-a4566103e27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_689226a7-c67b-4a17-ac76-3560a90be4bd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_EntityAddressPostalZipCode_689226a7-c67b-4a17-ac76-3560a90be4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_e6e326e6-4394-42e8-bc34-15405d34b553" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_CityAreaCode_e6e326e6-4394-42e8-bc34-15405d34b553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b936cf33-f3c2-4eef-97de-bd84789a9561" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_LocalPhoneNumber_b936cf33-f3c2-4eef-97de-bd84789a9561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_7af64221-294a-4509-96b5-8b02a3cb9a7b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_WrittenCommunications_7af64221-294a-4509-96b5-8b02a3cb9a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_a201bc26-6f61-439d-8387-095e04678f53" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_SolicitingMaterial_a201bc26-6f61-439d-8387-095e04678f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_fa248905-3a6c-4487-9cb5-82827178edb8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_PreCommencementTenderOffer_fa248905-3a6c-4487-9cb5-82827178edb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_80102d27-cd50-40f7-8aba-0f3d68289aeb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_80102d27-cd50-40f7-8aba-0f3d68289aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_48b1fc36-6b69-4076-8057-5635cd63327c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_EntityEmergingGrowthCompany_48b1fc36-6b69-4076-8057-5635cd63327c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_dac05e03-c38e-469c-bb22-c2e270c62485" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_Security12bTitle_dac05e03-c38e-469c-bb22-c2e270c62485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_81e42c29-fedf-4c32-be42-84bdda97bad1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_TradingSymbol_81e42c29-fedf-4c32-be42-84bdda97bad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a0f19538-5414-473c-8a25-84e5b27bad31" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_SecurityExchangeName_a0f19538-5414-473c-8a25-84e5b27bad31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_223d5575-aa4f-474f-9338-3b953a7e8009" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_EntityRegistrantName_223d5575-aa4f-474f-9338-3b953a7e8009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f8cab624-b7a0-4d2b-9a57-e2c9df49c110" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_EntityCentralIndexKey_f8cab624-b7a0-4d2b-9a57-e2c9df49c110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_16884722-34b7-40d1-858c-56081b3d1a7e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_61143619-94e6-429b-a547-5389be5e3e8a" xlink:to="loc_dei_AmendmentFlag_16884722-34b7-40d1-858c-56081b3d1a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>logoa31a.jpg
<TEXT>
begin 644 logoa31a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P *N\.7.;BYMSQXINDX\WC_ )=XS_JTZ.?GY_=^7]'?\' /_!4K_A#;&\^
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MQCJQ3BFI*.JGHI1<79Z]-;K6ZMK^EU%%%?8G\VA1110 4444 %%%% !1110
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M[XA_MM+<>'/#ZMX#^&]T?(N=+MIQ]NUB+'6ZG_N?],8\1_.0_F8!KR?]A/\
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M!M=#\,V,M_=3J 3L3G8@_B=SA47N2.]<1^R'^P3\+OV)=!OK7X>^&_[+FU3
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M5M7:2=^H_P""Q?\ P67O?VN]5O/AS\/+V[T_X8V5SMN[U6,,_BB6-NI_N6W
M*)_']]_[B>8?\$GO^"8&N?\ !0CXK"\U);K2/A?X:N -9U11M-W+_K!90_\
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M>Z/<Z9':M-:W-K]JMQ/;^>,>?$?XTKX//N+G53H8&Z766S?IU2\^I_5GA/\
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M;5ET'X:^#=.@M[;0M.8B#4;L?O)[VXDX\Z629Y).?W<?1.=[OX?7ZW?\$'_
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MQ1VNP_N4C_@V=_GSOYK@=2FN-1>XU"\:ZNKB\N9?.N9_W@GE^^_[S^*3Y_\
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MIO\ PK6^NO"O_"-W$6HWWBZ%G6#0$!P?NX\R=_GV0_\ +3G.Q-\@B_X)Q?\
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M\[(ER,EXB4^Z2A)?97YMZ]^P!\<_"^I?V?>_!OXEI= ]!X8O)@?^N;I'L?\
MX!7]45%<N8<'X3$U'4@W!O>VWW=#W>$/I(<0Y-@88#%4XXF,%:,IN2G;HFT[
M2MT;7-;=O0_F;^$'_!'']I;XTWUO]C^%'B#1[53S<^( -'%O_P  G\N3_OB,
MU]]?L@_\&S6A^$[^UU7XS>)AXJF!!?1-"\RTL^O/F79Q,XQ_<2 @_P 9K]:J
M*TP7!^ H/FFG-^>WW*QR<3?2-XLS6F\/AI1PT'_S[3Y__ Y-M>3BHM=S\V?^
M"QW_  2LN/CA^S-X*M?@MX;TJSNOA?=77V7PUIXBLH[JTNA'YYC'"/.)8(7Q
M)S)B0_.^$D_'^']@/XZ7>H_V>GP<^*GVKT_X16^X_P#(>*_JFK\E?^"[G_!6
MUO 5OJ7P1^&NHDZY=0F#Q1J\ Q_9\3_\N,+CCS7'^LD'$?W!\^\1\/$V2X&,
M7C:LG'965M6E9)?):^6I]7X&^)W%<ZD.%\!0CB$W*7/-R7LXRES3E-INZYI-
MI64I2E:[;5OQU\3:!=>$?$MUIUXJQWEC<&"=5G2=1(G'WT^1Z]\_X)Q?\$[?
M%7_!0KXRKHVF[]+\,Z81-KVN?9RT6G19_P!7'Q\\TG\"=L$G %<[^PW^Q7XM
M_;Q^.=GX'\,QO;0\7&K:G- 3;Z3;=))9/Y(G&]SVZC^CK]E/]E3PG^QK\%])
M\!^"[0VNDZ?\UQ-.P:ZU*X?;ON)I,?/(Q![;0 J($1$0?,\-\/O'5/:U5:DG
MKY^2_4_;/&KQ@APKA/[-P#4L=46FUJ:VYY)MJ[UY(OOS/1*^S^SI^SKX5_96
M^%&F^"?!.F#2]"TT<9&Z6YD_CEF?J\C]W/\ A7H]%%?KD(1A%1BK)'^>>*Q5
M;$UI8C$2<IR;<I-MMMZMMO5ML****HP"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKD_BE\1-%^$'PWU[Q
M9XBN4L]'\,V,U_?7!'^HBC0NY_(9I2DDKLNG3G4FJ=)7E)V26[;T27FV?*/_
M  60_P""CMO^P;^SHUKHDV[XC^,A+8Z"KIYGV!>1)>.#Q\F?W8.=\FSAT23'
MX"?#KX?^*OVC_BMIOAO0[.\U[Q1XNU 06ZD^=-<SR.=\LC_F[N_^VY]:[/\
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MHHHK8\\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K\Z_\ @X-@^*/CO]F'1O _PZ\&^)O$^F^(=0:]
M\1W&CV+WC6\%ILDAMGCC!DQ),4?<.GV7\*_12BN7'87ZSAY8=R<>96NCZ#A3
M/WD><8?-XTHU71ES*,KV;2T>C6L79I]&C^8W_@FU^Q-J7[7O[;WAOP#JUA?6
M^EV,W]J>)[:820S6UA!@R1.,^9'YA,< /\!G2OZ8M-T^WT;38;6WM_L]O;_N
MHH8Q\H':H_['M?M_VS[+;_:O)\CS]O[S9_<W]>M:E>=D>20RVG*,9<SD[MVM
MIT6[VU/L?%/Q0Q7&F,HXBI2]C3I0Y5#FYES-^]*]EJ[15K;104445[9^7!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140246172850512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Feb. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb.  02,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">IN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-06351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">35-0470950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Lilly Corporate Center<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Indianapolis,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">46285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">276-2000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ELI LILLY AND COMPANY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000059478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock (no par value)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock (no par value)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member', window );">7 1/8% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">7 1/8% Notes due 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member', window );">1.625% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Notes due 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member', window );">2.125% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.125% Notes due 2030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member', window );">0.625% Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.625% Notes due 2031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member', window );">6.77% Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">6.77% Notes due 2036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member', window );">1.700% Notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.700% Notes due 2049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY49A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A500NotesDue2033Member', window );">0.500% Notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.500% Notes due 2033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member', window );">1.625%&#160;Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Notes due 2043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member', window );">1.125% Notes due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.125% Notes due 2051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member', window );">1.375% Notes due 2061</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.375% Notes due 2061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A500NotesDue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A500NotesDue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>lly-20230202_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lly="http://www.lilly.com/20230202"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lly-20230202.xsd" xlink:type="simple"/>
    <context id="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-02-02</endDate>
        </period>
    </context>
    <context id="if99194a62558408da3eaf072492056d6_D20230202-20230202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-02-02</endDate>
        </period>
    </context>
    <context id="i66c6ae2792ff4b84a5ebbb81244eb4b3_D20230202-20230202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-02-02</endDate>
        </period>
    </context>
    <context id="i92c908dd435545b08496ae4273d1083b_D20230202-20230202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-02-02</endDate>
        </period>
    </context>
    <context id="i0c813e1023704a5987a3b758b72289a4_D20230202-20230202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-02-02</endDate>
        </period>
    </context>
    <context id="i26372fc909e145c3b425f3f58cb0c510_D20230202-20230202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-02-02</endDate>
        </period>
    </context>
    <context id="i2f5b20c214394dc8bc427934d0f5d13b_D20230202-20230202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A500NotesDue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-02-02</endDate>
        </period>
    </context>
    <context id="i696cdd16d5b148f9b8875c2c416d58e3_D20230202-20230202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-02-02</endDate>
        </period>
    </context>
    <context id="i63b8eaf69bd6416a9096eda3d15fc666_D20230202-20230202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-02-02</endDate>
        </period>
    </context>
    <context id="ibaff8c4f2c594068b5d1f826b384e156_D20230202-20230202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-02-02</endDate>
        </period>
    </context>
    <context id="i0c6077d2ffa84ee1b11a5af3affa1b67_D20230202-20230202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-02-02</endDate>
        </period>
    </context>
    <context id="i001eb9c620264821a3025473010e03ac_D20230202-20230202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-02-02</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV80L2ZyYWc6NzkwNWQ5M2ZjMDQxNDRjMmE1NzZkZThjMjYwYjNjYjAvdGFibGU6M2RhNjA0NDJmNmJjNDg3ZDkyOTM1MzllZGQ2Yzg1YmIvdGFibGVyYW5nZTozZGE2MDQ0MmY2YmM0ODdkOTI5MzUzOWVkZDZjODViYl8yLTEtMS0xLTE5NzIwNA_e466bccf-40c0-4056-a38f-8bec14a81e76">0000059478</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV80L2ZyYWc6NzkwNWQ5M2ZjMDQxNDRjMmE1NzZkZThjMjYwYjNjYjAvdGFibGU6M2RhNjA0NDJmNmJjNDg3ZDkyOTM1MzllZGQ2Yzg1YmIvdGFibGVyYW5nZTozZGE2MDQ0MmY2YmM0ODdkOTI5MzUzOWVkZDZjODViYl81LTEtMS0xLTE5NzIwNA_4abbc548-cc98-4d43-9ce5-52368243b882">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGV4dHJlZ2lvbjphNzRmMTliZWZkOGM0MTAwOTI4ZGNhZTQ4MDRmYTZjYl8xMTg5_faea5420-1047-49bd-97c2-2f2247377b8e">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGV4dHJlZ2lvbjphNzRmMTliZWZkOGM0MTAwOTI4ZGNhZTQ4MDRmYTZjYl8xNTk_569c3d59-1a3b-4f27-bceb-33903e69d40f">2023-02-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGV4dHJlZ2lvbjphNzRmMTliZWZkOGM0MTAwOTI4ZGNhZTQ4MDRmYTZjYl8xMTg1_2866e962-fb1f-42b3-bc27-3cf0d61ed912">ELI LILLY AND COMPANY</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6NWFhNTBhM2RlYmNlNGVkODlkNGJjYzgzNzEyMDk2ZmEvdGFibGVyYW5nZTo1YWE1MGEzZGViY2U0ZWQ4OWQ0YmNjODM3MTIwOTZmYV8wLTAtMS0xLTE5NzIwNA_2c6088a3-cbb8-4bd0-a57b-e8e196a2fdb2">IN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6NWFhNTBhM2RlYmNlNGVkODlkNGJjYzgzNzEyMDk2ZmEvdGFibGVyYW5nZTo1YWE1MGEzZGViY2U0ZWQ4OWQ0YmNjODM3MTIwOTZmYV8wLTItMS0xLTE5NzIwNA_2eded2bf-9fd2-489b-ba50-2f1424ff4841">001-06351</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6NWFhNTBhM2RlYmNlNGVkODlkNGJjYzgzNzEyMDk2ZmEvdGFibGVyYW5nZTo1YWE1MGEzZGViY2U0ZWQ4OWQ0YmNjODM3MTIwOTZmYV8wLTQtMS0xLTE5NzIwNA_e88bbfa3-b93f-4e1d-bacb-b606839c3ee9">35-0470950</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6OWJkNTRjY2VkZWFiNGFlMDk1NmU4NWZmNjU2MGFlNWEvdGFibGVyYW5nZTo5YmQ1NGNjZWRlYWI0YWUwOTU2ZTg1ZmY2NTYwYWU1YV8wLTAtMS0xLTE5NzIwNA_dbbabbef-98c8-4e26-b0a1-113c6f8a99f1">Lilly Corporate Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6OWJkNTRjY2VkZWFiNGFlMDk1NmU4NWZmNjU2MGFlNWEvdGFibGVyYW5nZTo5YmQ1NGNjZWRlYWI0YWUwOTU2ZTg1ZmY2NTYwYWU1YV8xLTAtMS0xLTE5NzIwNA_f96044e1-9fe0-46c3-8f9c-783249d66a84">Indianapolis,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6OWJkNTRjY2VkZWFiNGFlMDk1NmU4NWZmNjU2MGFlNWEvdGFibGVyYW5nZTo5YmQ1NGNjZWRlYWI0YWUwOTU2ZTg1ZmY2NTYwYWU1YV8xLTEtMS0xLTE5NzIwNA_a8c4a1f2-74d8-42f1-a49b-6647ed5393e1">IN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6OWJkNTRjY2VkZWFiNGFlMDk1NmU4NWZmNjU2MGFlNWEvdGFibGVyYW5nZTo5YmQ1NGNjZWRlYWI0YWUwOTU2ZTg1ZmY2NTYwYWU1YV8xLTItMS0xLTE5NzIwNA_24c7516a-37ba-44a8-8ae6-38f0986c1e4d">46285</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGV4dHJlZ2lvbjphNzRmMTliZWZkOGM0MTAwOTI4ZGNhZTQ4MDRmYTZjYl8xMTg2_a8868aad-6d03-4eb0-a765-9a55adf84fe8">317</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGV4dHJlZ2lvbjphNzRmMTliZWZkOGM0MTAwOTI4ZGNhZTQ4MDRmYTZjYl8xMTg3_a50263e6-3d51-4d4b-a083-29a8584b3b28">276-2000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6MzI3NzUxOGM5NTJjNDMxZjk1OTQ2YTY4ZmQxYThiMzIvdGFibGVyYW5nZTozMjc3NTE4Yzk1MmM0MzFmOTU5NDZhNjhmZDFhOGIzMl8wLTAtMS0xLTE5NzIwNA_f7fa0b97-e52e-4fa8-9c56-f8cc997b0243">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6MDgwMzI5OTg5MjRmNGUxOGFjOTYxZjRjZWZjNmQ1ZmEvdGFibGVyYW5nZTowODAzMjk5ODkyNGY0ZTE4YWM5NjFmNGNlZmM2ZDVmYV8wLTAtMS0xLTE5NzIwNA_4b3861dd-597f-4c2e-a855-55d25cbf71b5">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6MGNkMmE3NGU4NjdiNDViYzgzYmFmNzI5MmU4NWI4YjUvdGFibGVyYW5nZTowY2QyYTc0ZTg2N2I0NWJjODNiYWY3MjkyZTg1YjhiNV8wLTAtMS0xLTE5NzIwNA_7841b994-06ce-469d-bf30-1f6faf7e4596">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6OWQ5YmY2ZDRhZjgwNDFmZmIwNjFjMDA3Mjc4MTczYWEvdGFibGVyYW5nZTo5ZDliZjZkNGFmODA0MWZmYjA2MWMwMDcyNzgxNzNhYV8wLTAtMS0xLTE5NzIwNA_4d114017-84df-4127-8d84-804633a8c83e">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="if99194a62558408da3eaf072492056d6_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8xLTAtMS0xLTE5NzIwNA_9632c50e-ba9b-4d16-a6cd-0f6c2af91dbb">Common Stock (no par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if99194a62558408da3eaf072492056d6_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8xLTItMS0xLTE5NzIwNA_40e70fe2-f2c3-4451-b3af-e9a7a405cc39">LLY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if99194a62558408da3eaf072492056d6_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8xLTQtMS0xLTE5NzIwNA_bf4ca8f5-7453-4e67-9948-6d5d41c1d0b5">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i66c6ae2792ff4b84a5ebbb81244eb4b3_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8yLTAtMS0xLTE5NzIwNA_9d09c346-5e31-4acc-a475-a31869d86748">7 1/8% Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i66c6ae2792ff4b84a5ebbb81244eb4b3_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8yLTItMS0xLTE5NzIwNA_a213c462-bb80-4fd7-8e38-36907794ba1f">LLY25</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i66c6ae2792ff4b84a5ebbb81244eb4b3_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8yLTQtMS0xLTE5NzIwNA_626bb3dd-9ffb-4b14-96bf-d26a66b297b8">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i92c908dd435545b08496ae4273d1083b_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8zLTAtMS0xLTE5NzIwNA_fe6d812b-a875-4b6d-a49d-a0a270cdd371">1.625% Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i92c908dd435545b08496ae4273d1083b_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8zLTItMS0xLTE5NzIwNA_afae0a1d-a87b-474e-8515-892411e8de33">LLY26</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i92c908dd435545b08496ae4273d1083b_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8zLTQtMS0xLTE5NzIwNA_5b6f2e13-66a5-4ea4-8af3-7d9417f5e7be">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i0c813e1023704a5987a3b758b72289a4_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF80LTAtMS0xLTE5NzIwNA_0d6d33c5-f1ff-4b25-986d-72f8b0b9bc4e">2.125% Notes due 2030</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0c813e1023704a5987a3b758b72289a4_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF80LTItMS0xLTE5NzIwNA_7e401cfd-f7bd-42ee-bdb1-188a58c2b42c">LLY30</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0c813e1023704a5987a3b758b72289a4_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF80LTQtMS0xLTE5NzIwNA_332bd8bf-ab70-4516-bbba-8cca0da17d75">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i26372fc909e145c3b425f3f58cb0c510_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF81LTAtMS0xLTE5NzIwNA_379abb68-db4d-4930-b5ad-991584353ad0">0.625% Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i26372fc909e145c3b425f3f58cb0c510_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF81LTItMS0xLTE5NzIwNA_1c451bc9-0d6a-46d9-b7f2-9fe26abfff16">LLY31</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i26372fc909e145c3b425f3f58cb0c510_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF81LTQtMS0xLTE5NzIwNA_f5df9dc0-49fc-4c21-a1f3-a48cc7d70069">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i2f5b20c214394dc8bc427934d0f5d13b_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF82LTAtMS0xLTE5NzIwNA_20a872c0-958a-4295-ac91-53a2d825dcf4">0.500% Notes due 2033</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i2f5b20c214394dc8bc427934d0f5d13b_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF82LTItMS0xLTE5NzIwNA_97d2958a-5764-415e-b632-195f8d8ed4cf">LLY33</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i2f5b20c214394dc8bc427934d0f5d13b_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF82LTQtMS0xLTE5NzIwNA_20a0061b-6cbe-4dcf-9a3b-81dc58566768">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i696cdd16d5b148f9b8875c2c416d58e3_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF83LTAtMS0xLTE5NzIwNA_05f2ebdf-b85f-4c2d-a452-de0fb820d4e0">6.77% Notes due 2036</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i696cdd16d5b148f9b8875c2c416d58e3_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF83LTItMS0xLTE5NzIwNA_01ff47f7-0dd7-4835-89b0-a5797fd941c0">LLY36</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i696cdd16d5b148f9b8875c2c416d58e3_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF83LTQtMS0xLTE5NzIwNA_c5fada6a-8704-4503-8e18-df3efa406dd4">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i63b8eaf69bd6416a9096eda3d15fc666_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF84LTAtMS0xLTE5NzIwNA_fa0133b5-7623-46f2-b758-88b3424aa310">1.625% Notes due 2043</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i63b8eaf69bd6416a9096eda3d15fc666_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF84LTItMS0xLTE5NzIwNA_ecbc99e7-bbd7-4c29-98c7-bfd2c8683324">LLY43</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i63b8eaf69bd6416a9096eda3d15fc666_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF84LTQtMS0xLTE5NzIwNA_168e35c3-4645-4071-a278-6372dc34e510">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ibaff8c4f2c594068b5d1f826b384e156_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF85LTAtMS0xLTE5NzIwNA_9f6b4906-516f-4ede-8697-64b58fa5c62d">1.700% Notes due 2049</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ibaff8c4f2c594068b5d1f826b384e156_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF85LTItMS0xLTE5NzIwNA_792367d6-2ca3-4bdf-949d-37046049062e">LLY49A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ibaff8c4f2c594068b5d1f826b384e156_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF85LTQtMS0xLTE5NzIwNA_59090a7d-f92b-4c59-8755-be91851f0827">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i0c6077d2ffa84ee1b11a5af3affa1b67_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8xMC0wLTEtMS0xOTcyMDQ_41a1dbfc-9205-47e8-a285-695e4f6bbf75">1.125% Notes due 2051</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0c6077d2ffa84ee1b11a5af3affa1b67_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8xMC0yLTEtMS0xOTcyMDQ_ab409ebc-caba-48b2-8812-7d7e9ef19078">LLY51</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0c6077d2ffa84ee1b11a5af3affa1b67_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8xMC00LTEtMS0xOTcyMDQ_2ec49999-251d-4ace-ac72-c4c9bb17a500">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i001eb9c620264821a3025473010e03ac_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8xMS0wLTEtMS0xOTcyMDQ_ef8eb516-de1d-4655-8ad2-196d9648f297">1.375% Notes due 2061</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i001eb9c620264821a3025473010e03ac_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8xMS0yLTEtMS0xOTcyMDQ_77b23dfe-44a0-4ebf-ab6b-f145672f0dcf">LLY61</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i001eb9c620264821a3025473010e03ac_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGFibGU6M2IzMWVkMzdmMjBjNDVhOThlNjEyMTVmNzY3ZGIxNGQvdGFibGVyYW5nZTozYjMxZWQzN2YyMGM0NWE5OGU2MTIxNWY3NjdkYjE0ZF8xMS00LTEtMS0xOTcyMDQ_9bd851f8-9092-48d0-9b9d-799f497dcc9c">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MTg2ZDRlYzkyODRmZjRhNDFiODlkYTk0N2E1MTI1L3NlYzozNjE4NmQ0ZWM5Mjg0ZmY0YTQxYjg5ZGE5NDdhNTEyNV8xL2ZyYWc6YTc0ZjE5YmVmZDhjNDEwMDkyOGRjYWU0ODA0ZmE2Y2IvdGV4dHJlZ2lvbjphNzRmMTliZWZkOGM0MTAwOTI4ZGNhZTQ4MDRmYTZjYl8xMTg4_204dbe32-5a1b-49f6-9074-68a2ca4b6b54">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ M3E"5@=!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" "U.4)6QGH1_.X    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " "U.4)6F5R<(Q &  "<)P  $P
M    @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( +4Y0E:F
M\,_4]P8  !0Q   8              " @0T(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " "U.4)6GZ ;\+$"  #B#   #0
M    @ $Z#P  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( +4Y0E:7BKL<P
M !,"   +              "  182  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M +4Y0E89117U-P$  "<"   /              "  ?\2  !X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " "U.4)6)!Z;HJT   #X 0  &@
M@ %C%   >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "U
M.4)699!YDAD!  #/ P  $P              @ %(%0  6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     "0 ) #X"  "2%@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>12</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>11</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="lly-20230202.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="lly-20230202.htm">lly-20230202.htm</File>
    <File>lly-20230202.xsd</File>
    <File>lly-20230202_def.xml</File>
    <File>lly-20230202_lab.xml</File>
    <File>lly-20230202_pre.xml</File>
    <File>q422lillysalesandearningsp.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="52">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lly-20230202.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 52
   },
   "contextCount": 12,
   "dts": {
    "definitionLink": {
     "local": [
      "lly-20230202_def.xml"
     ]
    },
    "inline": {
     "local": [
      "lly-20230202.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lly-20230202_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lly-20230202_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lly-20230202.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 38,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 10,
   "memberStandard": 1,
   "nsprefix": "lly",
   "nsuri": "http://www.lilly.com/20230202",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230202.htm",
      "contextRef": "i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.lilly.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230202.htm",
      "contextRef": "i9512a284a9cd4c3fa0284960034a194d_D20230202-20230202",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 11,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "lly_A1.625NotesDueJune22026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.625% Notes Due June 2, 2026 [Member]",
        "label": "1.625% Notes Due June 2, 2026 [Member]",
        "terseLabel": "1.625% Notes due 2026"
       }
      }
     },
     "localname": "A1.625NotesDueJune22026Member",
     "nsuri": "http://www.lilly.com/20230202",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1.700Notesdue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.700% Notes due 2049 [Member]",
        "label": "1.700% Notes due 2049 [Member]",
        "terseLabel": "1.700% Notes due 2049"
       }
      }
     },
     "localname": "A1.700Notesdue2049Member",
     "nsuri": "http://www.lilly.com/20230202",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1125NotesDue2051Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.125% Notes due 2051",
        "label": "1.125% Notes due 2051 [Member]",
        "terseLabel": "1.125% Notes due 2051"
       }
      }
     },
     "localname": "A1125NotesDue2051Member",
     "nsuri": "http://www.lilly.com/20230202",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1375NotesDue2061Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.375% Notes due 2061",
        "label": "1.375% Notes due 2061 [Member]",
        "terseLabel": "1.375% Notes due 2061"
       }
      }
     },
     "localname": "A1375NotesDue2061Member",
     "nsuri": "http://www.lilly.com/20230202",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1625NotesDue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.625%\u00a0Notes due 2043",
        "label": "1.625%\u00a0Notes due 2043 [Member]",
        "terseLabel": "1.625%\u00a0Notes due 2043"
       }
      }
     },
     "localname": "A1625NotesDue2043Member",
     "nsuri": "http://www.lilly.com/20230202",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A2.125NotesDueJune32030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.125% Notes Due June 3, 2030 [Member]",
        "label": "2.125% Notes Due June 3, 2030 [Member]",
        "terseLabel": "2.125% Notes due 2030"
       }
      }
     },
     "localname": "A2.125NotesDueJune32030Member",
     "nsuri": "http://www.lilly.com/20230202",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A500NotesDue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.500% Notes due 2033",
        "label": ".500% Notes due 2033 [Member]",
        "terseLabel": "0.500% Notes due 2033"
       }
      }
     },
     "localname": "A500NotesDue2033Member",
     "nsuri": "http://www.lilly.com/20230202",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A6.77NotesDueJanuary12036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]",
        "label": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]",
        "terseLabel": "6.77% Notes due 2036"
       }
      }
     },
     "localname": "A6.77NotesDueJanuary12036Member",
     "nsuri": "http://www.lilly.com/20230202",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A625Notesdue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".625% Notes due 2031 [Member]",
        "label": ".625% Notes due 2031 [Member]",
        "terseLabel": "0.625% Notes due 2031"
       }
      }
     },
     "localname": "A625Notesdue2031Member",
     "nsuri": "http://www.lilly.com/20230202",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A718NotesDueJune12025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "7 1/8% Notes Due June\u00a01, 2025 [Member]",
        "label": "7 1/8% Notes Due June\u00a01, 2025 [Member]",
        "terseLabel": "7 1/8% Notes due 2025"
       }
      }
     },
     "localname": "A718NotesDueJune12025Member",
     "nsuri": "http://www.lilly.com/20230202",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class A [Member]",
        "terseLabel": "Common Stock (no par value)"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000059478-23-000025-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000059478-23-000025-xbrl.zip
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M9:"CH"W_^#N)\/OK+;C:$RH[AL[(^Z=KI (Y0BUSI3MNFJ[[&70[@MIVU.G
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M72E2[L0Y-H*$C@"$8PQ*7(I8A3KF0L>4"JE8*5(6C&,\1Z1@&]DP-!PE)$E
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M'O&(S:^S:["J^W8$_[7R;F?]_P-02P,$%     @ M3E"5CRD>1BV P  ^Q$
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M.%7PT6@BE*;>T0 R3"CY#=N[)OCCB=V4VXZ1N\\T+QOP P[0(+CNO1).HFN
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M<7)A=<;0$27/TU;W$JAGN-$D>MJ4?9&VM.JUY:<0UH&PKK,(?+N_$D9!;H4
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MW/T(CZZ\<TS-C:!K![.Y$N91I3-^)D-BJ\'\7#RT\E#3*[3R<Q0360WF:K3
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M5W/+!BPB25@7$(E%_3V,/!J07WD\"B>PLMY+\J?X2.MG'W5L>,SWIYH;CN6
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M0?T\ 4M Y(V)<X293EN&76\&B%VW>O![^P\>P>H/*'AY,R.[PU_B2^[$6FO
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M[8O%%[M2'@N.RW" :5F<@$^$]5?!P1)Z_4?3!OK,G2:-S(!O/ S\&5P56%?
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M7X0($=96KUTT?<J +;7CH;F\>:PZ.]H\(;M^63"=YOPZ/W;->6TP9VPI\SO
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M,3/]9F>^!8, N^U-5@@<I\JCY-F.1*\$ 5CL"YA;";C**,TY.SO775EB(5]
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M$%Y\4*+HA3Y_A/;C$!5KY2,K]M=&MD;94P)K2\$[P)5/)S%[D?_R,L]AX(&
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MGC*H(EE8,VRECFN/O H[7]=TE2J\#[M&TU5WX+T9^5I/73^H/_+* :EKIJ.
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MQ?!9ZL-*@ '8-]=//2"P,7S%O\]ZGO(@H<&0]_$U\Z)%DMK$-C$8DDPG:&3
M0D< 1OC/'8TXTFM+0(&[\!9\R21B'G>3EIQI0"A!M,AY8%^^1T84R!L^3OL
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M0I6G?<#CMS5;64O5Q7N/6S&F<1 R3$/5Y*T'@BH*^>NZ9BA3206DSM_JJEU
MZBSK^W8=I1,?"D'9EM961E55^6-35Q3T$).I3@<U05!%J<*6T395KX,Z!(M4
M"*H9QE!)7>/KLZQHK+H?K+>.0/L?K4UOXZ"C:]9Q%7\#(=2VE6E4!_Q457$V
MG?.TBRZRBO,1%RZQN/JS ;6<*^-OAX17>:7:$RSE(JL_GP;E=:I.C&6AAY0'
MJBKT<>$NKY@046X':!_D.M:#C!8*-HU@)E'#,4Z(Q_K)?L%O'!G\=S6"_JN/
M_WK[^MKH$1HDO!]Z7!34O@/0A-$TQPW>"UJNT;WQW:&"7"S@F 9K"X##W*F?
MX+R9+&2B:@C2@K!O1$G2?_8C]NT[/6:%*'/G"E&@_!W[Y7$1_^27EBRU/@<L
M )""/@J2B+K)-2[/6T6$@'F81LLES]^%WT+R,< %#Z>/+*Y>4E']4\3N*/>S
M>N\L!4#&Z\NKJT+I=:H 77F<JPJE;U8HW5RDI U\M1T+I3\'23^%_XR2L?_+
M_P=02P$"% ,4    " "U.4)6\W*2%;<?  "K&0$ $               @ $
M    ;&QY+3(P,C,P,C R+FAT;5!+ 0(4 Q0    ( +4Y0E8\I'D8M@,  /L1
M   0              "  >4?  !L;'DM,C R,S R,#(N>'-D4$L! A0#%
M  @ M3E"5L+SE,(I"@  RDP  !0              ( !R2,  &QL>2TR,#(S
M,#(P,E]D968N>&UL4$L! A0#%     @ M3E"5E#91]?B$   WZ0  !0
M         ( !)"X  &QL>2TR,#(S,#(P,E]L86(N>&UL4$L! A0#%     @
MM3E"5FL4QU;$"0  7%$  !0              ( !.#\  &QL>2TR,#(S,#(P
M,E]P<F4N>&UL4$L! A0#%     @ M3E"5MG9^*?46P  M+D% !X
M     ( !+DD  '$T,C)L:6QL>7-A;&5S86YD96%R;FEN9W-P+FAT;5!+!08
1    !@ & (X!   ^I0     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
